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ABSTRACT
T-cells are lymphocytes that make up part of the adaptive arm of the
immune system, and are essential for efficient protection from and eradication of
viruses and pathogens. T-cells not only play an important role in protection from
external agents, but also regulate and prevent activation towards self-peptides
and detect and remove erratically growing cells. Alterations in T-cell activation
and suppression contribute to auto-immunity, immunocompromised disorders,
and cancer progression.
The immune system, and T-cells in particular, provides daily surveillance,
recognition and destruction of aberrant cells. Although the immune system is
proficient at suppressing malignant progression, tumor cells acquire various
methods of immune evasion. Myelodysplastic Syndrome (MDS) is a premalignant dysplastic disorder of the bone marrow characterized by ineffective
hematopoiesis and clonality in the myeloid lineage, where lack of immune
response has been implicated in the propensity for progression to acute myeloid
leukemia (AML). Leukemia progression is associated with the acquisition of
complex genetic abnormalities. Alterations in immune system regulation have
been implicated in various stages of the disease process, although the role of the
immune system in response to several therapies in MDS has not been fully
discovered.
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Lenalidomide is a small molecule therapeutic preferentially effective in
MDS patients with an interstitial chromosome 5q deletion (del(5q)). Improved
erythropoiesis has also been reported to occur in 20-30% of low-risk, non-del(5q)
patients. Although lenalidomide is a potent immunomodulatory drug that
potentiates T-cell and NK-cell responses, the T-cell compartment in MDS is
highly deregulated by aberrant repertoire skewing, decreased function and
abnormal naïve and memory cell homeostasis.

The presence of lymphoid

infiltrates in the bone marrow of lenalidomide-responsive patients suggests that
T-cells may participate in the hematopoietic response, but it is unclear if
lenalidomide is capable of reversing these functional T-cell defects.

We

therefore assessed immunological changes in low-risk MDS patients before and
after 16-weeks of lenalidomide therapy, and assessed the relationship to
erythroid response. Although MDS T-cells were anergic prior to treatment, we
have shown that T-cells in responders have a significant increase in antigeninduced proliferative response and T helper type-1 (Th1) cytokine production (IL2, IFN-γ, TNF-α) compared to non-responders. The change in function positively
correlated with an increase in naïve T-cells and a decrease in memory cells,
indicating that lenalidomide has immunomodulatory activity to reverse anergy in
MDS.
Although it is known that lenalidomide may increase T-cell activation and
proliferation in the absence of co-stimulatory signals, a direct mechanism of
action has yet to be elucidated. Since CD28 is one of the most important costimulatory molecules deregulated in cancer, we therefore set out to determine if

viii

the expression of CD28 was essential for lenalidomide’s mechanism in T-cells.
We knocked out CD28 expression in healthy donor T-cells, and sorted on
inherently deficient, CD28null, T-cells that accumulate in older healthy donors and
found that lenalidomide-induced proliferation and function were completely
ablated within the CD28null subset.

These data indicate the immunotyrosine-

based activation motifs (ITAMs) on the intracellular domain of the CD28 receptor
are necessary for lenalidomide action.
Interestingly, during the natural aging process, repeated exposure to
antigens results in the accumulation of CD28null T-cells that are phenotypically
distinct and functionally deficient due to excessive proliferative history in vivo.
We therefore examined whether CD28 expression on MDS patient T-cells
affected responses to lenalidomide, and if this could be used as a predictive
biomarker of responsiveness. We found that patients who fail lenalidomide
therapy had higher CD8+ Terminal Effector Memory (TEM), which are inherently
CD28null, and that non-responders had an overall increase in CD4+ and
CD8+CD28null T-cells, as well as an increase in CD28null cells within the TEM
compartment compared to hematologic responders.
We then sought to determine the particular protein target of lenalidomide
responsible for increased CD28 receptor signaling in T-cells. Several targets in a
variety of cell types have been postulated, although the direct mechanism in Tcells is unclear. Our group has previously shown that lenalidomide inhibits the
activity of two haplodeficient phosphatases located within the commonly deleted
region (CDR) on chromosome 5q in the MDS myeloid clone, Protein
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Phosphatase 2A (PP2A) and Cdc25c. PP2Ac is known to bind CD28 and is
hypothesized to inhibit T-cell co-stimulation.

Therefore, it is plausible that

lenalidomide and other IMiDs inhibit the phosphatase activity of PP2A which
leads to increased activation of T-cell proximal signals dependent on CD28
expression. We examined this hypothesis using molecular modeling and virtual
screening and found that all of the IMiDs (lenalidomide, pomalidomide, and
thalidomide) can theoretically interact with the catalytic pocket of the PP2A
heterotrimer, potentially inhibiting PP2Ac activity. In vitro phosphatase activity
assays supported these findings as lenalidomide-inhibition of PP2Ac activity was
seen in both ad293 and Jurkat cell lines, and in primary T-cells. Mutations of
theorized lenalidomide hydrogen-bond sites within the catalytic pocket of PP2A
rendered the enzyme catalytically dead, indicating that these are important
residues for enzymatic activity, but unfortunately could not be used to determine
if lenalidomide activity was disrupted by mutation of those sites.
These data together suggest that the ability of lenalidomide to augment
immune activation in vivo in MDS patients, and potentially other diseases, is
extremely important to patient response. Also, that CD28 expression on T-cells is
essential for lenalidomide immune-mediated tumor eradication through CD28
downstream signaling, and potentially through inhibition of PP2A. These results
are useful in designing future lenalidomide-combination therapy trials in other
hematologic and solid malignancies, and could be used to help stratify patients
for future therapeutic decisions in MDS and other malignancies.
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CHAPTER 1
Background
A note to the reader: Portions of this chapter have been previously published in
a review article in the journal Advances in Hematology, McDaniel et al. 2012. (1)
and has been reproduced here with permission from the publisher.
T-cells
T-cells, along with B-cells and Natural Killer (NK) cells make up the
lymphoid compartment, with T- and B-cells comprising the adaptive arm of the
immune system. The immune system has both innate and adaptive mechanisms
to seek out, recognize, and destroy foreign pathogens such as bacteria, viruses,
helminthes, etc., and even erratically-growing autologous cells. T-cells express
antigen-specific receptors (T-cell Receptors, TCRs) that allow them to specifically
recognize over a million different protein epitopes, both self- and non-self, to
stave off attack from the thousands of potential pathogens we encounter on a
daily basis.
T-cell development. The creation of a lymphocyte compartment occurs in
the thymus where cells are selected for their ability to recognize and destroy
foreign pathogens while displaying tolerance towards self-antigens. Immature “Tcell

precursors”

are

produced

from

hematopoietic

stem

cells

during

hematopoiesis within the bone marrow, and home to the thymus through a
variety of chemo-attractants, including CCL25 and CCL21, where they develop
1

and mature (2, 3). The thymus is a primary lymphoid organ with several different
structural features, including a cortex and medulla that separate and organize the
various stages of lymphocyte development. When an immature lymphocyte
enters the thymus, it goes through several CD4/CD8 “double negative” stages
(DN1 to DN4) marked by lack of surface receptor expression or down-regulation
of CD44 and CD25 (4). During the DN3 stage, the TCR-β chain undergoes
irreversible V(D)J recombination via the recombination activating gene (RAG),
generating a unique sequence (5). T-cells then continue to the DN4 stage where
they undergo VJ TCR-α chain gene rearrangement. T-cells are then either CD4
or CD8 positive, and undergo positive thymic selection. Positive selection
involves expression of relatively rare, low-affinity self-peptides that are necessary
to ensure the creation of a functional αβTCR. Full maturation of the TCR is not
complete until self- MHC-recognition within the thymus (6). Interestingly, the
TCR-α chain can undergo multiple VJ recombination events to allow for the
creation of a functional positively-selected TCR (7, 8). T-cells surviving positive
selection then undergo negative selection, where high-affinity binding of the TCR
and secondary signal induction promotes apoptosis of self-reactive T-cells,
preventing them from being released into the periphery where they may induce
auto-immune reactions (9, 10).
T-helper and cytotoxic T-cells. There are two distinct subsets of T-cells
involved in adaptive immunity, namely CD4+ T-helper cells (Th) and CD8+
cytotoxic T-cells (Tc). CD4+ cells are helper T-cells that recognize antigen
peptides presented on MHC-II expressed on antigen presenting cells. Activation
2

of Th cells induces proliferation and robust cytokine secretion to provide support
to other helper T-cells and Tc cells in a variety of pathogenic settings. CD4+ Tcells can differentiate in the periphery into a variety of different T-helper subtypes
based upon their cytokine secretion profile, including Th1, Th2, Th17, T follicular
helper (Tfh) and induced regulatory T-cells (iTreg) (11). The differentiation
decision is actually governed by cytokine exposure within the microenvironment
of the non-differentiated CD4+ T-cells, and to some extent on the strength of the
TCR-antigen interaction (12). Exposure of naïve CD4+ T-cells to various
cytokines in the presence of TCR-stimulation induces epigenetic changes at
DNA-loci that encode for subset-specific cytokines (13-15). It was originally
thought that commitment to one T-helper cell lineage was a permanent
epigenetic imprint, but recent evidence suggests that inter-conversion between
the different lineages can be induced using epigenetic modifying drugs (16), and
may occur between Th1 and Th2 cells under appropriate inflammatory conditions
in vivo (17).
Each T-helper subset has been defined based upon unique gene
expression profiles, and their roles in providing T-cell cytokine help in different
pathological settings. Interferon-γ (IFN-γ) and interleukin-12 (IL-12) polarize
CD4+ T-cells towards the Th1 lineage, characterized by production of IFN-γ and
IL-2 and activation of the T-bet transcription factor (18). Th1 are involved in
cellular immunity and are extremely important in providing help to CD8+T-cells
during microbe infection, as well as enhancing anti-tumor activity of CD8+ tumorantigen specific T-cells (19, 20). IL-4 polarizes CD4+ T-cells to become Th-2
3

through induction of GATA3 transcription factor expression. These cells secrete
IL-4, IL-5, and IL-13 cytokines important for humoral B-cell support and they are
essential for protection against helminthes and other multicellular pathogens
(21). Th17 or “T-inflammatory” cells are a more recently defined population of Thelper cells that require (ROR)γt transcription factor expression and are induced
through exposure to IL-6, IL-23, IL-21, and TGF-β (22). Th17 cells secrete IL-17
and IL-22, and play a role in the clearance of extracellular bacteria and fungi and
are involved in exacerbating GVHD after bone marrow transplantation (22, 23).
Aberrant Th1 and Th17 cell activation is involved in organ-specific auto-immunity,
whereas Th2 erratic signaling is involved in allergy and asthma. Another recently
defined subset of T-helper cells are the T-follicular helper cells (Tfh) which
migrate to follicles to provide help in B-cell maturation and antibody production
and are induced through IL-21 exposure (24-26) and activation of Bcl-6 (27).
Another unique subset of CD4+ T-cells are the regulatory T-cells defined
by forkhead box P3 (denoted Foxp3 in mice and FOXP3 in humans) expression,
which help to maintain immune system homeostasis and regulate effector T-cell
responses to prevent auto-immunity. Mice lacking T-regs have overwhelming
Th1 and Th2-induced autoimmunity

(28-30). There are two types of Tregs,

including natural Tregs (nTregs) that are produced and develop in the thymus
and are characterized through CD4+CD25+ expression, and TGF-β-induced
Tregs (iTregs) that are induced to express Foxp3 and become regulatory T-cells
in the periphery (31, 32). Tregs are also involved in promoting immune evasion in
the setting of tumors by suppressing tumor-specific cytotoxic T-cells.
4

CD8+ T-cells are cytotoxic T-cells (Tc) that recognize peptides presented
through MHC-I not only on antigen presenting cells, but all cells within the body.
CD8+ T-cells are also called “T-killer” cells because activation of these cells
against a target cell causes them to release perforin and granzymes directly into
the target cell, activating the caspase cascade and inducing cell death (33-35).
Like CD4+ T-cells, there are different Tc subsets that have different cytokine
profiles similar to their corresponding CD4 counterparts (i.e. Tc1, Tc2, Tc17),
although the function of the separate subsets in different pathological settings
has not been as extensively defined as in CD4 T-cells (36, 37).
Memory T-cells. Once naïve T-cells, both CD4+ and CD8+ are stimulated
by their cognate antigen, they expand and eradicate the pathogen, and then
during the contraction phase either become memory T-cells or die. The T-cell
fate is usually governed by the strength of signal through the TCR, as well as
concurrent cytokine activation (38). A majority of the activated population will
undergo activation induced cell death (AICD) and will be eliminated, while others
will die due to neglect, and the remainder of the population will become memory
cells.
There are three types of memory T-cells: Central Memory (TCM), Effector
Memory (TEM), and Terminal Effector Memory (TTEM). Central Memory T-cells are
CD45RA-CCR7+CD62L+, with expression of the latter two receptors necessary
for cell extravasation and migration to the secondary lymphoid organs where they
have limited effector function until secondary stimulation (39). TCM

provide

reactive memory and upon secondary activation will proliferate and differentiate
5

into effector cells (40). Effector Memory T-cells are CD45RA-CCR7-CD62L-,
express high amounts of perforin, and home to peripheral tissues where they are
activated rapidly to produce effector cytokines and provide immediate protection
against pathogens (41, 42). The third memory population is CD45RA+CCR7CD62L-

Terminal

Effector

Memory

cells,

characterized

as

“end-stage”

differentiation. These cells are thought to accumulate following intense cytokinedriven proliferation (43). Interestingly, CD45RA+ TTEM cells are generally
senescent with a majority of the population lacking the CD28 co-stimulatory
molecule, and increase through aging and in autoimmune diseases (44, 45). This
particular memory population is found only in humans, as murine T-cells do not
down-regulate the CD28 receptor. Recently it has been determined that the
senescence of these cells is due to decreased p38-MAPK pathway signaling,
and since they have normal telomerase activity, their senescence is potentially
reversible (46). There is some controversy though about the stages of memory
cell development. It is unclear if T-cells undergo linear transformation from naïve
to TCM and then progress to TEM, and then TTEM after multiple rounds of
stimulation (47, 48), or if there is asymmetric memory development. Interestingly,
it was recently discovered that there is asymmetric memory T-cell division in
response to antigen re-challenge, indicating that there may be a subset of T-cells
that remain in the TCM subset after activation (49).
Memory T-cells are an extremely important component of the adaptive
immune system, as they persist throughout a person’s lifetime through
homeostatic proliferation to provide antigenic memory and swift reaction time to
6

antigen re-exposure. Memory T-cells turnover at a very slow rate in the absence
of their cognate antigen through exposure to the common-γ chain cytokines
Interleukin-7 (IL-7) and IL-15, allowing for continued maintenance of the memory
compartment (50-53). IL-7 and IL-15 are necessary for memory maintenance of
both CD4+ and CD8+ T-cells, but not memory induction (52, 54, 55). CD4+ T-cell
help, likely through IL-2 secretion, is an absolute requirement for the generation
of functional CD8+ T-cell memory (56). Factors driving the generation of CD8+
effector vs. memory cells are not completely understood, but it seems to require
the expression of the transcription factor eomesodermin (eomes, a member of
the T-bet family of transcription factors) and exposure to IL-2 (57, 58). Alterations
within homeostatic regulation of the memory cell compartment are found in aging
individuals, cancer, and several autoimmune disorders, alluding to the
importance of memory T-cell generation and maintenance.

The strength of

antigen stimulation, exposure to homeostatic cytokines, and the phenotype of the
memory compartment are all extremely important in shaping the immune reaction
to pathogens and cancer.
Aging in the immune system. As with many other systems in the body,
aging induces profound alterations within both the innate and adaptive arms of
the immune system, and in turn affecting the immune system’s ability to respond
to and eradicate pathogens. Unlike T and B-cells, NK cell numbers actually
increase with age, and normal healthy aging is associated with only a slight
decrease in proliferation and response to IL-2 (59). Overall, NK-cell cytotoxicity
and IFN-γ production decrease on a “per cell basis” as one ages, but only
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significant decreases in cytotoxicity are associated with increased morbidity and
mortality associated with infections and poor influenza vaccination response (6062). The humoral immune response is also dramatically altered through aging.
The phenotype of the B-cell compartment is altered through a decrease in overall
naïve B-cell numbers and an increase in memory B-cells, leading to overall
decreased BCR diversity (63, 64). The B-cells, like T-cells, also have a decrease
in co-stimulatory molecule expression, antibody affinity, and a decreased ability
for antibody isotype switching which contributes to an overall reduction in
infection-fighting capacity (63, 65) . Included with these changes are deficiencies
within the T-cell compartment leading to inefficient T-cell help and contributing
greatly to overall decreased humoral immune response (66) .
Aging also has a particularly pronounced effect on the phenotype and
function of the T-cell compartment, namely alterations in memory T-cell
development and differentiation, as well as cellular senescence (67). Thymic Tcell production essentially stops once a child has finished growing and has
sufficiently seeded the peripheral T-cell compartment with naïve T-cells (68). The
thymus begins to involute around the age of 20, replacing the functional thymic
cortex and medulla with adipose tissue, and causing a steady decline in the
release of new naïve T-cells into the periphery (69, 70). Therefore, naïve T-cells
produced in young humans must persist and survive throughout one’s lifetime.
Steady-state naive T-cell numbers are maintained in the periphery via
homeostatic, mostly TCR-independent, mechanisms through cytokines like IL-7
and IL-15 (71, 72). But, the ability for naïve T-cells to continually divide and keep
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populating the T-cell compartment diminishes with age because of the
accumulated numbers of memory T-cells that proliferate and crowd the T-cell
niche in both the CD4 and CD8 subsets.
Not only does the production of naïve T-cells decline with age, but also the
function of memory T-cells that have undergone many rounds of homeostatic
proliferation, and newly-generated memory T-cells as well. Poor memory T-cell
response and the loss of cognate T-helper cell function among CD4+ T-cells are
one of the causes of poor vaccine efficacy in the elderly (73, 74). Aged T-cells
have decreased calcium flux after TCR stimulation, as well as decreased ability
to produce IL-2 and other cytokines, although some pro-inflammatory functions
are enhanced (75, 76).
One of the most profound and consistent phenomenon observed with
aging and the immune system is the accumulation of terminally differentiated
CD45RA+CD28- T-cells (77, 78), which can also be accelerated through chronic
CMV infection (79, 80). Humans over the age of 80 have approximately 10-15%
CD4+CD28- T-cells and approximately 60% CD8+CD28- T-cells (44) that have
decreased T-cell receptor diversity (81) and decreased ability to proliferate in
response to cognate antigen (82). CD28- terminally differentiated memory T-cells
are hypo-responsive in their inability to fully support stimulation with the lack of
the co-stimulatory molecule, demonstrating a decreased ability to secrete IL-2 or
induce telomerase expression, and are more susceptible to activation induced
cell death (AICD) due to their long proliferative history in vivo (83-85). The
accumulation of CD8+CD28- T-cells negatively impacts immune responses to
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foreign antigens in the elderly because these cells proliferate and expand,
constraining the adaptive immune response through competition for available
space within the T-cell niche, restricting naïve T-cell homeostatic proliferation.
There are several documented molecular mechanisms for the perpetual
loss of CD28 surface expression on terminally differentiated T-cells. Enhanced
TNF-α exposure has been experimentally shown to decrease CD28 surface
receptor expression on T-cells, suggesting that these cells are produced in
inflammatory conditions, and persistent infection, like CMV, has been
demonstrated to drive their accumulation and induce pre-mature aging of the
immune system (86, 87). Interestingly, CD4+CD28- T-cells are readily triggered
by inflammation and thereafter perpetuate and amplify the inflammatory process
(88). CD28 surface expression is transiently down-regulated after ligation with
B7-1/2 or with anti-CD28 antibody ligation, but is usually re-expressed on the cell
surface within 48 hours. Under persistent T-cell stimulation, CD28 expression is
gradually reduced and eventually lost without the ability to re-induce expression,
suggesting that transcriptional silencing controls receptor down-regulation.
Utilizing a CD28-reporter gene construct method, it was discovered that T-cells
lacking CD28 are not able to induce expression of CD28 due to a lack of protein
complex formation that binds to the CD28 initiator (89-91). Two proteins within
the complex, nucleolin and A isoform of heterogeneous nuclear riboprotein-D0
(hnRNP-D0A), have been shown to be essential for the induction of CD28
expression, and a coordinate loss of alpha-beta INR bound-complexes
contributes to decreased CD28 expression in senescent T-cells (89).
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Overall, there are significant changes in all the immune system
compartments associated with the deterioration of the immune system during
aging, but the accumulation of CD28- T-cells is a significant player contributing to
the reduced overall responsiveness to pathogens and viruses, and likely to the
decreased ability to eradicate tumor cells. Exhausted T-cells usually develop in
the presence of highly replicated viruses and tumors through increased inhibitory
molecule interaction (like PD-1) and along with the increased expression of TNFα in the tumor microenvironment, contributing to increased immune senescence
(92, 93). The impact of the accumulation of CD28- T-cells on the immune
system’s ability to eradicate tumors has not been fully elucidated, but is important
to understand in relation to the use of immunotherapeutic vaccines for cancer.
T-cell activation. TCR binding to cognate ligand presented on antigen
presenting cells induces receptor clustering, phosphorylation of downstream
signaling molecules, and activation of transcription factors leading to proliferation,
cytokine production and effector/regulatory functions.

There are multiple

important co-receptors in the B7-CD28 and TNF-Receptor superfamilies involved
in this process, such as CD28, cytotoxic T lymphocyte antigen 4 (CTLA-4),
inducible co-stimulatory molecule (ICOS), programmed cell death protein-1 (PD1) and 4-1BB and OX40, respectively. These receptors have both activating and
inhibitory properties involved in shaping and altering the T-cell response upon
association with cognate ligand (94, 95), as seen in Figure 1.
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Co-stimulatory receptors. Co-stimulatory receptors, including
CD28, ICOS, 4-1BB, and CD40L, expressed on T-cells are necessary for a fully
competent T-cell response. CD28 appears to be the most important costimulatory molecule involved in activation and proliferation, and will be described
in great detail later in this chapter. ICOS is a more recently discovered costimulatory molecule that is not natively expressed on naïve T-cells, but is upregulated quickly on effector T-cells upon activation, indicating it may provide costimulatory signals to activated T-cells (96-98). Ligation of ICOS by ICOS-L (B7h)
on APCs is involved in co-stimulation of both Th1 and Th2-type effector
responses (99, 100), and is necessary in regulating immunoglobulin-isotype
class switching and germinal center formation (101). 4-1BB and OX40 are
members of the tumor necrosis factor receptor (TNFR) family that bind to 4-1BBL
and OX40L respectively on antigen presenting cells, and are also involved in costimulation. The expression of both molecules is triggered by TCR/CD28 ligation,
as well as IL-2 binding, and the ligation of these receptors increases T-cell
proliferation and up-regulation of anti-apoptotic molecules such as Bim, Bcl-xl,
and Bcl-2 (102-104). Their role appears to depend on T-cell activation, with 41BB and OX40 ligands important in regulating the frequency of effector memory
cells generated during recall responses while enhancing T-cell function directly
through induction of IL-4 and IFN-γ production (105).
Co-inhibitory receptors. CTLA-4 is the best characterized T-cell
co-inhibitory receptor that is essential in regulating T-cell activation and
tolerance. CTLA-4 expression on naïve T-cells is low and becomes up-regulated
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after activation to intrinsically regulate CD28 signaling through competition for
B7-1/2 (CD80/CD86) binding (106, 107) (Figure 1). In naïve T-cells, CTLA-4
accumulates in the golgi and is released to the external membrane fraction upon
activation (108), where it binds to B7-1 or B7-2 to disrupt CD28 stabilization at
the immune synapse, effectively shutting off T-cell co-stimulation and signaling
(109). The importance of CTLA-4 in regulating T-cell homeostasis not only lies in
its ability to down-regulate activation after stimulation, but in inducing tolerance
and suppression mechanisms of regulatory T-cells as well. CTLA-4 knockout
mice die within 3-4 weeks of age due to lethal polyclonal CD4+ T-cell dependent
lymphoproliferation and autoimmunity, leading to multi-organ failure (110-112).
Interestingly, the intracellular cytoplasmic tail of CTLA-4 is not always necessary
to induce T-cell inhibition, as mouse models with mutant intracellular motifs were
still able to regulate T-cell signaling. This data suggests that CTLA-4 attenuates
T-cell activation by physical competition of the extracellular domain binding to
B7-1/2 ligands and displacement of CD28 (113, 114).
PD-1 is another co-inhibitory molecule from the B7-CD28 family that is
highly expressed on activated CD4+ and CD8+ T-cells, B-cells, and myeloid cells
(115). PD-1 ligation by either PD-L1 or PD-L2 has been shown to abrogate TCRmediated proliferation and cytokine production in activated T-cells, and cannot be
overcome through strong CD28 co-stimulatory signals (116, 117). PD-1 only
exerts inhibitory activities in the presence of TCR signaling, and does so through
activation of SHP-2, which de-phosphorylates signaling molecules within the
proximal-TCR signaling cascade, halting TCR-induced activation (118). PD-L1
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expression on tumor cells inhibits tumor-specific killing by CD8+ cytotoxic T-cells,
and up-regulation of PD-1 expression on functionally exhausted antigen-specific
T-cells indicates the negative role PD-1 plays in T-cell activation and
proliferation. On the reverse, PD-1 plays an extremely important role in regulating
normal T-cell homeostasis and prevention of auto-immunity, as PD-1 knockout
mice of the C57BL/6 strain develop progressive arthritis and a lupus-like
syndrome (119), or early onset cardiomyopathy in the Balb/c strain (120). These
data all demonstrate the importance of co-inhibitory and co-stimulatory molecules
in shaping T-cell responses under normal conditions, and how erratic expression
or activation of either can lead to severe pathologic conditions.
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Figure 1. T-cell co-receptors that shape responsiveness to activation. T-cell
co-receptors bind to ligands expressed on antigen presenting cells (APCs), left.
CD40L, CD28, 4-1BB and ICOS are co-stimulatory molecules that
enhance/activate downstream signaling upon TCR ligation. PD-1 and CTLA-4
are co-inhibitors that turn off and inhibit T-cell activation after TCR ligation.

CD28
CD28 structure. CD28 is a 44 kDa co-stimulatory receptor on T-cells that
synergizes with the TCR to induce downstream intracellular signaling, cytokine
production, actin rearrangement, and prevent apoptosis and anergy upon ligation
with CD80/CD86 (B7-1/2) on APCs (121, 122). CD28 is expressed on the
surface of T-cells as a glycosylated, disulfide-linked homodimer (123), with an
extracellular ligand-binding domain, a transmembrane region, and an intracellular
cytoplasmic tail containing several activation sequences, as CD28 lacks intrinsic
kinase activity (Figure 2). The cytoplasmic tail of CD28 contains two
immunoreceptor tyrosine-based activation motifs (ITAMs), namely a YMNM (i.e.
YXXM) SH-2-binding domain and PYNPP SH-3-binding domain, that are
essential for the binding of kinases and adapter molecules (124). The tyrosine
(Y191) in the YMNM motif allows for binding of p85 subunit of PI3K and the
guanine nucleotide exchange factor Vav1 through the Grb2 adaptor molecule
(Figure 2) (124-126).
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Figure 2. Schematic of CD28 receptor and signaling motifs. CD28 is a
transmembrane receptor comprised of an extracellular ligand binding domain, a
transmembrane domain (TM), and an intracellular tyrosine-rich region. The
cytoplasmic tail contains 2 ITAMs (bold) that are phosphorylated upon activation
(by Lck) to recruit signaling molecules, some of which are indicated above (Grb2
and p85).

CD28 signaling cascade. Knockdown of CD28 leads to decreased T-cell
activation and reduces memory T-cell generation (127), and its expression is
necessary for proliferation and homeostasis of regulatory T-cells (128). When the
TCR encounters its respective antigen presented on MHC, tyrosines within the
ITAM on the TCR/CD3 complex become phosphorylated by src-related kinases
Lck and fyn (129, 130). Phosphorylation of ITAM motifs on the TCR recruits
kinases Zap70, adaptor molecule Grb2, phosphoinositide 3-kinase (PI3K) and
other SH-2 domain containing proteins to the TCR/CD3 complex, and further
promote downstream activation and nuclear localization of transcription factors,
like NF-kB and AP-1 (129, 131, 132). This activation cascade is essential, but
not sufficient, for full TCR-induced signaling response.
Important kinases in the TCR signaling pathway, like lck, phosphorylate
tyrosines within the YXXM and proline-rich PYAPP motif on the cytoplasmic
region of CD28 leading to activation of PI3K, MAPK, and NF-κB pathways
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(Figure 3) (124, 126, 133, 134). The PYAP motif also associates with Filamin A,
an actin binding protein involved in scaffolding for lipid raft generation which is
necessary for the formation of a functional immune synapse (135).

Figure 3. Schematic of T-cell signaling. TCR ligation induces activation of
various kinases, including lck, which phosphorylates tyrosines within the
intracytoplasmic tail of CD28, increasing downstream signaling and activation of
PKC-θ, MAPK, and other signaling pathways. These pathways lead to the
activation of classic T-cell transcription factors like AP-1, NFAT-1, and NF-κB that
induce secretion of the T helper type 1 (Th-1) cytokines IL-2, tumor necrosis
factor-α (TNF-α), and Interferon-γ (IFN-γ), as well as promote proliferation and
prevent apoptosis.

There has been substantial difficulty in elucidating distinct signaling
cascades emanating from TCR ligation versus CD28 ligation, as there is
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significant cross-talk between the two pathways.

Vav1 activation has been

shown to be necessary for superagonistic CD28 antibody activation of T-cells in
the absence of TCR ligation, alluding to its importance in CD28-mediated
signaling (133, 136). Vav is extremely important in the activation of Rho GTP-ase
and actin mobility/re-organization (137). The ability of CD28 to signal in the
absence of the TCR has been hypothesized, as seen in microarray data of Tcells stimulated with anti-CD28 alone. Activation with only anti-CD28 results in an
independent gene expression profile in comparison to anti-TCR signaling in the
absence of CD28, but the significance of this remains controversial (138, 139).
The relative importance of the ITAM motifs on the CD28 receptor in the activation
of T-cells is also debated. Mutation of the proximal YXXM motif (Y170F) inhibited
PI3K binding, but had no overt effects in vivo (140), although mutation of the
proline-rich PYAP motif (to AYAA) abrogated proliferation and IL-2 and other
cytokine expression (141). These data collectively suggest that signals
emanating from the YXXM motif may be redundant, or that TCR ligation has
sufficient activation. The activation of PYAP-binding proteins, however, appears
to be essential for T-cell activation and most likely unique to CD28 signaling.
CD28 is necessary for Interleukin-2 production. The requirement of
CD28 expression for transcriptional activation of the inerleukin-2 (IL-2) promoter
is not contested. A 50-fold increase in IL-2 secretion by both transcriptional and
post-transcriptional mechanisms occurs after CD28 co-stimulation compared to
TCR activation alone (142). Moreover, CD28 knockout mice retain the ability to
proliferate in response to stimulation, although reduced compared to WT
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counterparts, but completely lack the ability to express IL-2(143).

The p85

subunit of PI3K binding to the YMNM motif leads to activation of the Akt pathway,
inducing phosphorylation of mTOR, IκB and other molecules that induce the
activation of NF-κB, c-fos and c-jun (AP-1), and OCT-1 that induce IL-2 gene
expression and the up-regulation of pro-survival proteins like Bcl-xL and Bcl-2
(144) (Figure 3).
Although PI3K activation is important to augment CD28 signaling,
signaling through activation of PKCθ-Carma-1/Bcl-10/Malt-1 (CBM) complex
pathway is specific and necessary for CD28-specific induced transcription factor
activation of NF-κB and cAMP response element-binding protein (CREB) (145).
Vav activation of Protein lipase Cγ1 (PLC-γ1) downstream of CD28 ligation
activates diacylglycerol (DAG), that in turn induces PKC-θ activation and
recruitment to the immunological synapse (146). Although Vav signaling is not
specific to CD28, Vav activation is indispensible for CD28 mitogenic signaling
(147). PKC-θ then phosphorylates caspase-recruitment domain-containing
membrane associated guanylate kinase protein-1 (CARMA-1), allowing binding
to Bcl10 creating the CBM complex that activates NF-κB and other transcription
factors like CREB and NFAT to bind to the CD28 response element (CD28RE)
on the IL-2 promoter (148, 149). NFAT, AP-1, and NF-κB have several DNA
binding-sites on the IL-2 promoter, but it was discovered that the binding of these
transcription factors to a specific region 180bp upstream of the IL-2
transcriptional start site was induced specifically by CD28 ligation (CD28RE), and
were necessary to induce IL-2 expression (150). A transgenic mouse model of a
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dominant negative form of T-cell specific promoter-driven CREB determined that
dysfunctional CREB led to decreased proliferation and IL-2 production, cell-cycle
arrest and apoptosis (151-153). Taken together, these discoveries suggest that
the binding of transcription factors to the CD28RE is essential for IL-2 production
and induced only through specific signals emanating from ligation of the CD28
receptor.
Negative regulation of CD28 signaling. There are several mechanisms
inherent within T-cell biology to prevent hyper-activation of T-cells in the absence
of co-stimulation, non-specific activation in the presence of low-affinity ligands,
and to “turn off” signaling during T-cell contraction phase. Negative signaling
regulation is necessary, in general, for prevention of autoimmunity.
Cbl-b. One protein in particular that contributes to CD28 regulation
and is involved in anergy induction is casitas b-lineage lymphoma-b (cbl-b). Cbl-b
is an E3 ubiquitin-ligase in the cbl-protein family that can either mono-ubiquitinate
proteins to alter signaling cascades or poly-ubiquitinate proteins, targeting them
for degradation via the proteasome pathway (154). The importance of cbl-b in
inhibiting the activation of the CD28 signaling cascade was first discovered
through the use of cbl-b knockout mice (155, 156). In 2000, two groups
independently published results from germline cbl-b knockout mice. Homozygous
cbl-b deficient (cbl-b-/-) mice were hyper-responsive to TCR stimulation and
intolerant to self-antigens, allowing the T-cells to proliferate and induce IL-2
cytokine production in the absence of CD28 ligation leading to generalized
autoimmunity in vivo. Crossing the cbl-b-/- mice with CD28-/- mice reversed the
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hyperactivation and autoimmune phenotype, demonstrating the importance of
cbl-b in CD28 regulation (157).
In the absence of CD28 ligation, cbl-b mono-ubiquitinates the p85 subunit
of PI3K, prohibiting its recruitment to the CD28 receptor and preventing activation
of the PI3K pathway (158). PKC-θ is also mono-ubiquitinated and targeted for
lysosomal degradation by cbl-b, inhibiting activation of NFAT and NF-κB (159).
Cbl-b regulation of CD28 is extremely important in self-tolerance and prevention
of non-specific T-cell activation, but these processes are also involved in anergy
induction. Repeated TCR stimulation in the absence of co-stimulatory molecule
ligation drives the expression of several anergy inducing cell cycle inhibitors,
tyrosine phosphatases, and cbl-b which help establish anergy (160, 161). Upregulation of cbl-b expression further inhibits the PI3K and PKC-θ pathways, as
well as degradation-inducing ubiquitination of PLC-γ, leading to unstable immune
synapses and defects in calcium mobilization (159, 162).
TCR ligation in the presence of CD28 activation is necessary to produce a
strong enough signal allowing for sustained activation of PKC-θ and PI3K,
inducing

full

T-cell

activation.

After

CD28

ligation,

activated

PKC-θ

phosphorylates cbl-b, increasing cbl-b auto-ubiquitination and proteosomal
degradation demonstrated through PKC-θ-cbl-b co-IP experiments, and elevated
cbl-b expression in PKC-θ-/- T-cells (163, 164).
PP2A. Phosphatases have an important role in regulation of T-cell
activation and reversion back to a resting phenotype upon stimulus removal, but
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their study has been quite less extensive in the past years compared to that of
kinases. CD45, SHP1, and SHP2 are protein tyrosine phosphatases (PTPs) with
importance in both positive and negative regulation of T-cell signaling via the
TCR, Zap-70, Syk, MAPK, and many other signal cascade molecules (129).
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is also
essential in regulating many cellular processes, including signal transduction
pathways, cytoskeleton dynamics, cell-cycle regulation and cell mobility (165,
166), as well as negative regulation of T-cell signaling. Protein phosphatase 2A
(PP2A) is a heterotrimeric holoenzyme composed of an “A” scaffolding subunit
and “C” catalytic subunit that together comprise the PP2A enzymatic core.
Proper function and regulation of PP2A is regulated through the association of
the core heterodimer to variable “B” regulatory subunits (167, 168). The ability of
the PP2A core to trimerize with the over 16 members of the four B subfamilies
(B, B’, B’’, B’’’) confers substrate specificity (166, 169), which is essential for
proper PP2A regulation as PP2A makes up over 1% of total cellular protein in
some tissues.
PP2A has also been shown to have an important role in the negative
regulation of IL-2 production in T-cells in systemic lupus erythematosus (SLE)
(170, 171). Katsiairi et al, demonstrated that PP2A is over-expressed in SLE
patients, and this over-expression leads to decreased CREB phosphorylation,
inhibited CREB binding to the IL-2 promoter, and abrogated IL-2 expression.
PP2A can directly de-phosphorylate CREB to affect its transcriptional regulation,
as well as de-phosphorylate CARMA-1 to dissociate the CBM complex and
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down-regulate T-cell activation (172, 173). PP2A interacts with both the CD28
and CTLA-4 receptors (174) to directly regulate their signaling pathways. It has
recently been shown that the important motifs on CTLA-4 for interaction of the A
and C PP2A subunits are a lysine rich region and amino acid Y182, respectively
(175). Dissociation of this core a-c heterodimer from CTLA-4 likely inactivates
downstream targets of TCR signaling (like Akt) because treatment with Okadaic
Acid, a known inhibitor of PP2A, reverses this Akt inhibition (175). Since CTLA-4
and CD28 are structurally homologous and bind to shared ligands (174), it is
likely PP2A that binds to similar motifs on CD28, however, this has not been
experimentally verified. Although the exact binding motif is not determined, an in
vitro kinase assay with lck and CD28 showed that the addition of PP2A removed
lck-induced CD28 phosphorylation, indicating that PP2A may have a role in
directly reversing CD28 ITAM activation (174) and inhibiting downstream
signaling.

Tumor Immunology
Tumor immune surveillance (elimination). Immunosurveillance of
cancer cells was first postulated by Dr. Burnet in the 1970s, and is now a wellestablished principle thought to contribute not only to the quantity, but also the
quality, or immunogenicity, of a tumor during development (176-178). Dr. Robert
Schreiber and colleagues first coined the 3 steps contributing to tumor
immunoediting (elimination, equilibrium and escape) back in the early 2000s, and
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the importance of proper immune regulation in cancer management continues to
be experimentally supported today (179, 180). An active and healthy immune
system is critical for managing tumor development at the sub-clinical level,
evidenced through increased rate of spontaneous tumor generation in
immunodeficient mice (177, 181), and in immune-suppressed patients.
Immunosuppressed patients due to organ or bone marrow transplantation have a
3-100 fold increase in their susceptibility to develop certain malignancies (182,
183), including heart transplant patients who have shown a 25 times higher
prevalence of lung tumors compared to the general population (184). Since the
1990s, there have been several studies demonstrating better prognosis and
longer survival in patients who had evidence of tumor infiltrating lymphocytes
(TILs) within solid tumor biopsies, indicating that the immune system plays a key
role in eliminating tumors at the sub-clinical and clinically detectable level (185189).
Tumor immune equilibrium. Mechanisms regulating innate and adaptive
immune responses are carefully orchestrated to detect and remove infected,
transformed, or erratically growing cells within the body on a daily basis,
preventing tumor formation. Tumors eventually overcome immune detection
through an equilibrium stage where the immune system actually “edits” tumors
and selects cells that can evade immune detection. Tumor immune-editing has
been demonstrated through several mouse tumor models. Transplantation of an
immunogenic tumor through multiple rounds of immune-responsive hosts lead to
reduced immunogenicity, and the eventual inability to eliminate the tumor (190,
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191). The immune system is able to eliminate only those cells that it can
recognize and kill, leaving behind tumor cells that have reduced immunogenicity
and a survival advantage facilitated through inherent genetic instability within the
tumor environment (192). Immune editing is also evidenced through tumors that
have been grown in an immunocompromised host (i.e. RAG-/-) that are rejected
fairly easily when removed and transplanted into an immune-efficient host. This
immunoediting process occurs prior to any clinically detectable lesion in humans,
as the immune system is able to eliminate a majority of the abnormal cells, and
the length of time that it takes for the tumor to eventually overcome the innate
and adaptive immune systems is not known.
Tumor immune escape.
Mechanisms of escape. During the equilibrium stage, the immune
system eventually becomes overwhelmed, or evaded, by the malignant cells and
the tumor progresses into a clinically detectable lesion. At this point, the point at
which clinicians and researchers are trying to eradicate the lesion, the tumor has
already acquired several advantages to suppress the immune system and
survive. Tumors can induce peripheral T-cell tolerance through antigen nonresponsiveness (lack of co-stimulation) or skewing of the T-cell functional
response towards a non-tumor cytotoxic phenotype (i.e.: Th2 or Th17) (193,
194).
Tumors have several mechanisms of inducing anergy/non-responsiveness
and evading immune detection (Figure 4). These mechanisms include down25

regulation of class I human leukocyte antigen (HLA) molecules that allow for the
detection of tumor associated antigens (195), increased recruitment of immature
myeloid cells, called myeloid-derived suppressor cells (MDSCs), into the tumor
environment (196, 197), increased recruitment of regulatory T-cells into the tumor
(198), and various alterations in T-cell co-stimulatory/co-inhibitory molecules
expressed on the tumor. One important mechanism of escaping T-cell
recognition is through down-regulation of co-stimulatory molecules, leading to
anergy or non-responsiveness towards the tumor cells (as reviewed in (199)).
Lack of co-stimulation through B7-1 molecule even in the presence of low affinity
antigenic stimulation (similar to that seen in the tumor environment) can also
render CD8+ T-cells susceptible to PD-1/PDL-1 inhibition and suppress
activation (200). Up-regulation of T-cell co-inhibitory molecules that shut down Tcell responsiveness and potentially increase apoptosis of tumor-reactive T-cells
is another major mechanism of escaping immune recognition (201-203). B7-H1
(PDL-1) over expression is associated with tumor grade and staging in a variety
of solid tumors and several hematologic malignancies (204-208), including
myelodysplastic syndrome (209), and expression of B7-H2, a ligand for CTLA-4,
is associated with poor prognosis in acute myeloid leukemia (AML) (210).
Therefore, these co-stimulatory and co-inhibitory molecules have become
attractive immunotherapeutic targets from both the T-cell and tumor cell vantage
point.
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Figure 4. Mechanisms of tumor immune escape. Tumors utilize a variety of
mechanisms to evade detection by the immune system. Tumors recruit
regulatory T-cells, as well as immature myeloid cell (MDSCs) that suppress T-cell
activation through a variety of mechanisms. Tumors also are able to downregulate co-stimulatory molecules (B7-1) and HLA-I to evade antigen
presentation, while up-regulating co-inhibitory molecules and Fas to induce T-cell
suppression and apoptosis.

Immunotherapeutics. The importance of proper CD28 activation
and the role of PD-1 and CTLA-4 activation in shutting down the immune
response have translated into the development of several drugs targeting these
pathways in cancer. As described above, tumor cells up-regulate co-inhibitory
ligands like B7-H1 and B7-H2, which bind to and activate the T-cell inhibitory
receptors CTLA-4 and PD-1.

Recently, the use of a human anti-CTLA-4

monoclonal antibody (ipilimumab) has been approved for the treatment of
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metastatic melanoma and is shown to increase tumor rejection and prolong
survival, where it disrupts the CTLA-4/B7 interaction and increases CD4+ and
CD8+ recruitment to the tumor environment (211-213). The blockade of PD-1
signaling also improves T-cell function, and the use of anti-PD-1 antibodies are
currently in development and clinical testing in several hematologic and solid
malignancies (214, 215).
Not only are monoclonal antibodies being developed to block the binding
of inhibitory molecules to ligands on T-cells, but increasing the binding of costimulatory molecules has also been utilized. Cellular vaccine immunotherapies
that over-express the B7-1 molecule have been tested and demonstrated some
clinical efficacy in melanoma and non-small cell lung cancer (NSCLC) (216, 217)
but this method does not account for increased expression of inhibitory
molecules that dampen the activation signal. The success of these therapies
support the idea that greater immunotherapy efficacy may be achieved with
combination therapies, utilizing anti-inhibitory molecule antibodies, with costimulatory molecule engagement to produce a robust anti-tumor immune
response, overcoming tumor-immune tolerance.

Lenalidomide and the immunomodulatory drugs (IMiDs®)
Thalidomide and the generation of IMiDs®. Lenalidomide (Revlimid,
CC-5013) is a second-generation synthetic derivative of glutamic acid and
thalidomide

analogue

with

anti-angiogenic,
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anti-tumorigenic,

and

immunomodulating activity. Thalidomide was initially discovered in the 1950s and
was approved in Europe and Asia from 1957-1961 for distribution to pregnant
women as an antiemetic drug, until it was banned because of an association with
teratogenicity, including phocomelia, and peripheral neurophathy. The birth of
thousands

of

children,

dubbed

“thalidomide

babies”

with

severe

limb

malformations became popularly known as the “thalidomide tragedy”, and blackboxed usage of the drug worldwide. There are multiple proposed mechanisms for
thalidomide-induced teratogenicity, some stemming from proposed differences in
targets or off-target effects due to the chirality of the molecule. It was thought that
the S-enantiomer of thalidomide induced teratogenic effects, whereas the Renantiomer was non-toxic (218), leading to the idea that purification of
enantiomer-specific molecules might have prevented the thalidomide tragedy. It
was later discovered that thalidomide is able to interconvert between the R and S
forms in vivo, suggesting that purification of a specific enantiomer would not have
prevented this tragedy, and could not be used therapeutically in pregnant women
(219).
Therapeutic usage of thalidomide was revitalized in the mid-1960s by Dr.
J. Sheskin in Jerusalem who administered thalidomide as a sedative to a
critically ill male patient with erythema nodosum leprosum (ENL), an extremely
painful

inflammatory

complication

of

lepromatous

leprosy

(220,

221).

Surprisingly, thalidomide healed the inflammatory skin lesions and overall
disease burden of the patient. The ability of thalidomide to inhibit inflammation
through down-regulation of TNF-alpha was ultimately discovered as the
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mechanism for thalidomide efficacy and immune modulating effects in this
disease (222, 223). The efficacy of thalidomide demonstrated through usage in
ENL ultimately revitalized the drug, and stimulated development of several
structurally-related compounds with anti-inflammatory activity for the treatment of
autoimmune disorders such as Rheumatoid Arthritis (RA) (224), systemic lupus
erthymatosus (SLE) (225), and Behcet’s disease (226).
Creation of synthetic modifications to the thalidomide backbone led to the
discovery of lenalidomide and pomalidomide, which demonstrate 500-fold greater
immunomodulatory potency and safer side effect profile compared to the parent
drug (227, 228) (Figure 5). Not only are lenalidomide and pomalidomide more
potent immune-modulating drugs, but these agents are better tolerated (229).

Figure 5. Structures of the immunomodulatory drugs. Thalidomide,
C13H10N2O4, (thal, top), lenalidomide, C13H13N3O3, (len, bottom left), and
pomalidomide, C13H11N3O4, (pom, bottom right) collectively make up a class of
small molecules called immunomodulatory drugs or “IMiDs”. The parent
compound, thalidomide, was altered to generate len and pom. Light red boxes
highlight an amine group added to the fourth carbon of the phthaloyl ring in the
thal-derivatives. Light blue boxes indicate the carbonyl of the 4-amino-substituted
phthaloyl ring shared by pom and thal. * indicates chiral carbon on all molecules.
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Lenalidomide in Myelodysplastic Syndrome. Lenalidomide was first
investigated in MDS because of its potent anti-TNF-α activity, and TNF is thought
to contribute to disease pathogenesis in these patients. Lenalidomide is
approved by the U.S. Food and Drug Administration for the treatment of low- or
intermediate-1 risk and del(5q) Myelodysplastic Syndrome (MDS), and was the
first karyotype-specific drug of its kind (230, 231). MDS is a heterogeneous
grouping of bone marrow failure disorders characterized by ineffective
hematopoiesis leading to various cytopenias, dysplasia in one or more myeloid
lineages, and an increased risk of transformation to acute myeloid leukemia
(AML). The International Prognostic Scoring System (IPSS) is used to stratify
MDS into several risk categories (low, intermediate-1, intermediate-2, high)
based upon cytologic features, blast counts, the number of cytopenias, and
cytogenetics (232). These risk categories have distinct survival patterns and
increased risk for AML progression as you go from low to high risk MDS. MDS
with an interstitial deletion on the long arm of chromosome 5 (del(5q)) is one of
the most common MDS chromosomal abnormalities that imparts a unique lower
risk phenotype (233). Hematopoetic stem cell transplantation (HCT) is the only
known curative treatment for MDS, but several other treatments such as 5-aza
(234), anti-thymocyte globulin (ATG) (235), and lenalidomide have had great
success in extending patient survival. Described herein are known effects of
lenalidomide in mediating erythropoiesis and disease management.
Effect on hematopoiesis. Anemia and red blood cell transfusion
dependence ultimately leads to mortality in a significant portion of low, and high31

risk MDS patients. Lenalidomide was able to induce 63% transfusion
independence in low-risk MDS patients, and 83% transfusion independence with
a 75% complete response rate in the del(5q) subtype (230). There are many
postulated mechanisms for lenalidomide’s efficacy in MDS, namely associated
with its ability to augment erythropoiesis and induce apoptosis within the myeloid
clone. Reversal of anemia in these patients has potentially been attributed to
expansion of hematopoietic progenitors and erythroid bursts (236, 237), as
demonstrated through increases in these populations after treatment of normal
CD34+ bone marrow progenitors with lenalidomide. An erythroid gene signature
of responsiveness to lenalidomide in non-del(5q) MDS also indicated that
patients who respond to lenalidomide therapy have decreased expression of
erythroid differentiation genes that are enhanced through lenalidomide treatment,
ultimately enhancing erythropoietin (EPO) signaling and reducing anemia (238).
RPS14 and MDM2. RPS14 is among 44 genes within the CDR of
MDS 5q-syndrome that is involved in the impaired erythropoiesis and macrocytic
anemia phenotype. It was discovered through an a RNAi screen that the specific
downregulation of RPS14 alone was able to promote the erythroid phenotype
seen in del(5q) MDS patients, and this data along with the finding that del(5q)
patients express half of the amount of RPS14 found in non-del(5q) MDS patients,
suggests that haploinsufficiency of this gene alone is sufficient to induce impaired
erythropoiesis (239, 240). Loss of RPS14 expression has been shown to lead to
increased p53 expression in these patients, subsequently increasing expression
of p53 target genes like p21 and other cell cycle regulators that prohibit
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movement through the cell cycle and induce apoptosis (241). Loss of, or
mutations within, ribosomal processing proteins leads to nucleolar stress, and
sequestering and inducing degradation of murine double-minute protein 2
(MDM2), allowing for p53 stabilization (242). Recently, Wei et al. demonstrated
that lenalidomide can promote p53 degradation in erythroid progenitors through
inhibition of the auto-ubiquitination of MDM2 (243). MDM2 auto-ubiquitination
prevents its binding to p53. Free and active MDM2 usually binds to, an polyubiquitinates p53, targeting p53 for proteosomal degradation and preventing it
from halting the cell cycle progression. MDS patients with del(5q) were shown to
have inherently increased p53 levels in the bone marrow that were then
decreased after lenalidomide treatment. The upregulation of p53 expression after
lenalidomide failure also suggests p53 induction could be involved in resistance
to lenalidomide (243).
PP2Acα and Cdc25c. Lenalidomide has been shown to not only
reverse apoptosis within the erythroid compartment, but also directly induce
apoptosis of the myeloid clone in del(5q) MDS (244, 245), likely through inhibition
of the haplo-insufficient phosphatases PP2Acα and Cdc25c located also within
the CDR (246). PP2A and Cdc25c are key proteins that regulate the G2-M cell
cycle checkpoint. Through direct or indirect mechanisms, a decrease in PP2Ac
and Cdc25c gene dosage allows for lenalidomide-induced inhibition of these
phosphatases, preventing cell cycle progression and inducing apoptosis (246). It
has also been demonstrated that lenalidomide upregulates the expression of the
tumor suppressor SPARC (247), suggesting another means by which
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lenalidomide induces apoptosis of the dysplastic myeloid clones in MDS,
although the target in this pathway has not yet been determined.
Cereblon. Recently, a direct target of IMiD-binding has been
identified. Although the potential function of this protein in MDS is not clear,
cereblon (CRBN) is a 51kDa protein that mediates thalidomide teratogenicity in
humans (248). Ito and colleagues utilized thalidomide-conjugated beads in
competitive binding assays to demonstrate that CRBN directly binds to
thalidomide, and can induce teratogenic effects in zebrafish and chicken
embryos, similar to those seen in humans. CRBN is a ubiquitously expressed
highly conserved protein that was first discovered as an ionic channel regulator in
the brain involved in memory and learning (249, 250). CRBN binds to calciumactivated potassium channels in the brain (250, 251), chloride channels in the
retina (252), and AMP kinase in eukaryotic cells (253). The homozygous R419X
nonsense mutation in CRBN deletes the C-terminus region and is associated
with familial mild mental retardation (254). Forebrain-specific CRBN knockout
mice also demonstrate memory and learning deficits (255). In vivo, CRBN forms
a functional E3 ubiquitin ligase complex with DNA damage binding protein-1
(DDB1), Cul4A and Roc1 that bind to and poly-ubiquitinate target proteins,
targeting them for proteosomal degradation.
Thalidomide was shown by Ito et al. to not necessarily disrupt formation of
the CRBN-DDB1-Cul4A complex, but inhibit its inherent auto-ubiquitination and
E3 ligase activity, disrupting downstream pathways involved in physical and
mental development (248). Although the role of CRBN in thalidomide-induced
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teratogenicity has been established, the role of CRBN in hematologic
malignancies and immune cells is not completely clear. Decreased expression of
CRBN was recently shown in two separate studies to be associated with
resistance to lenalidomide- and pomalidomide-induced apoptosis in multiple
myeloma cell lines (256, 257). Lopez-Girona et al. also demonstrated that
knockdown of CRBN in primary T-cells reverses the ability of lenalidomide and
pomalidomide to increase IL-2 and TNF-α production (257), implicating a
potential role for the protein in immune modulating activity. Although these data
support that CRBN is a lenalidomide target, the role of CRBN in proliferation and
function of both hematologic cells and immune cells is not understood.
Examination of the natural targets of CRBN in other cells besides the brain will
help us to better understand how CRBN is affecting responses to lenalidomide,
and potentially lead to generation of other compounds to counteract acquired
lenalidomide resistance.
Immune-modulating effects. The immunomodulating effects of
lenalidomide are also thought to contribute to erythroid responsiveness in MDS,
where it acts to alter immune homeostasis and modulate inflammation within the
bone marrow microenvironment. The ability of thalidomide to down-regulate
monocyte-derived TNF-α production originally explained the potent antiinflammatory properties of the drug in SLE and other auto-immune disorders
(222). Enhanced TNF-α secretion within the bone marrow microenvironment has
been implicated in erythroid apoptosis in MDS, which is down-regulated through
lenalidomide treatment (258). Increased expression of other inflammatory
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cytokines, IL-6, IL-8, and IL-32, as a result of increased TNF-α levels are also
implicated in bone marrow failure, and are decreased after lenalidomide
treatment (259).
Early reports of the presence of bone marrow lymphoid aggregates
in lenalidomide-responsive MDS patients also implicated immune modulation in
hematological responses to this agent (231). Although the alteration of T-cell
homeostatic regulation in MM by lenalidomide has been described, the direct
effects on the lymphoid compartment in MDS patients, and the relationship to
response, has not been studied (260). Neuber and colleagues show that
lenalidomide can enhance antigen-specific activity of T-cells, as well as increase
conversion of naïve antigen specific T-cells to memory cells. A similar increase in
central memory T-cells was observed by Noonan et al (261) in MM patients that
received lenalidomide in combination with the pneumococcal 7-valent conjugated
vaccine (PCV) to establish the principle of vaccine combination therapy.
Interestingly, the increase in PCV-specific antibody and cellular responses were
specific to the vaccination schedule favoring administration of lenalidomide prior
to PCV vaccine.

Another hematologic malignancy, B-Chronic Lymphocytic

Leukemia (B-CLL), is associated with dysfunctional T-cell activity (262, 263) with
defects in actin polarization at the immune synapse (264). Treatment with
lenalidomide in CLL restored IL-2 and IFN-γ secreting CD4+ and CD8+ T-cells to
normal levels (253) and reversed the suppressive signals blocking lytic synapse
formation (264). One of the aims of this dissertation was to examine the immune
compartment within MDS patients to see if lenalidomide can alter immune
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homeostasis and cytokine production in vivo to further elucidate the role of
increased immune activation in the treatment of MDS.
Immunomodulatory capacity of lenalidomide in other hematologic
malignancies. Lenalidomide is not only approved for the treatment of MDS, but
has potent immune-modulating effects in a variety of other hematologic
malignancies. Lenalidomide alone or in combination therapy enhances the costimulatory capacity of T-cells and antibody-dependent cell-mediated cytotoxicity
(ADCC) by NK cells in diseases such as MM, B-CLL, and Non-Hodgkin’s
Lymphoma (NHL), although the direct molecular targets have yet to be
elucidated. The known effect of lenalidomide in promoting immune detection and
eradication of these diseases by lymphocytes is described in this section.
Enhanced T-cell co-stimulation and signaling. Lenalidomide is
able to enhance the proliferative and functional capacity of T-cells, which
augments immune activity through a variety of mechanisms. Thalidomide was
first shown to augment T-cell proliferation and cytokine production in the absence
of co-stimulatory molecules without direct mitogenic activity (265). When a T-cell
encounters cognate tumor antigens presented by antigen presenting cell (APCs),
there is an increase in a variety of co-stimulatory molecules, most importantly
CD28, that enables a fully competent signal response by T-cells (266). As
described above, the absence of CD28-APC interaction (Signal 2) in the
presence of T-cell Receptor ligation (Signal 1) leads to inactivation or anergy of
naïve T-cells. Thalidomide, and to a greater extent lenalidomide, induces IL-2,
IFN-γ, and TNF-α secretion (265) in the absence of CD28 stimulation, suggesting
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that the drug somehow activates the co-stimulatory-dependent signaling cascade
initiated by Signal 2 (267).
Both Signal 1 (TCR) and Signal 2 (co-stimulation) are necessary for IL-2
production leading to the hypothesis that lenalidomide and the other IMiDs
function somewhere within this co-stimulatory pathway (129, 268, 269) (Figure
6).

LeBlanc et al. showed that lenalidomide acts to increase tyrosine-

phosphorylation in the intracellular domain of the CD28 receptor in the absence
of co-stimulatory molecules (270). Although it is not known if lenalidomide acts
directly to induce phosphorylation, the presence of downstream signaling events
after treatment such as NF-κB p65 translocation to the nucleus, and cytokine
production, suggests that this pathway may be important for lenalidomide’s
immunomodulatory effect (270). Others have shown that the activation of PKC-ζ
and NFAT-2 are important mediators of cytokine production after IMiD treatment
(271). However, a conflicting report showed that PKC-θ activity and AP-1 DNA
binding was increased, without an increase in NF-κB, OCT-1, and NFAT
transcription factor binding, which adds to the controversy about lenalidomide’s
T-cell-associated molecular mechanism of action (272, 273) (Figure 6). These
controversial results, however, may be attributed to the methods used for T-cell
stimulation, namely TCR stimulation versus calcium channel activation,
respectively. Görgün et al. showed that lenalidomide and pomalidomide reduce
Suppressor of Cytokine Signaling-1 (SOCS1) expression in T-cells, which is an
important negative regulator of cytokine signaling (274). Even when treated with
IFN-γ to induce SOCS1 expression, the drug was capable of blocking this
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inhibitory response and potentiating TCR/anti-CD28 co-stimulation in effector Tcells (274). Although reduction in a suppressive signal may be important, this
would not be expected to generate unique responses, such as IL-2, that
specifically replace the need for a co-stimulatory signal.
Effects on Tregs. In addition to the activation of effector T-cells,
there is a valid concern about the potential effect of IMiDs on regulatory T (Treg)
cells that may deter anti-tumor immunity by suppressing immunosurveillance
(177, 275). In this regard, lenalidomide and pomalidomide were shown to inhibit
the expansion and function of Tregs by downregulating the expression of FOXP3
(276, 277). The preferential augmentation of CD8+ cytotoxic T-cells and
inhibition of regulatory T-cells makes this drug a very interesting and
potentially valuable therapeutic candidate to augment immunotherapy
responses in cancer patients.
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Figure 6. Schematic of various T-cell signaling pathways up-regulated after
lenalidomide treatment. Lenalidomide is known to have no direct mitogenic
activity, therefore it cannot induce proliferation upon TCR ligation alone. Upon
TCR ligation, lenalidomide (LEN) increases phosphorylation of tyrosines within
the intracytoplasmic tail of CD28, through an unknown mechanism, increasing
downstream signaling and activation of PKC-θ, MAPK, and potentially other
signaling pathways. It is controversial which transcription factors are ultimately
increased upon lenalidomide treatment (indicated by a question mark). Upregulation of these pathways potentially reverse T-cell defects, aid in breaking
tolerance, and leads to greater CD4+ T-cell help to DCs, NK cells, and CD8+ Tcells, augmenting eradication of the tumor cells.

Increased Natural Killer cell recognition and cytotoxicity of
leukemia cells. In addition to the potentiating effect on T and B cells,
immunomodulatory drugs have a profound effect on the innate immune
response, namely Natural Killer (NK) cells. NK cells are an important component
of the innate immune system where they play major roles in tumor rejection, viral
clearance and DC regulation (278-280). Thalidomide was shown to enhance the
cytotoxic effects of NK cells, as well as increase their cell numbers in MM
patients (281). This enhanced killing effect requires cytokine support from
accessory lymphocytes, like T-cells, as there is no measurable increase in direct
killing of the K562 human leukemia cell line by purified NK cells in the presence
of high doses of lenalidomide or pomalidomide (282). PBMCs depleted of NK
cells were not able to kill K562 at all, nor were PBMCs in a transwell experiment,
suggesting that NK cells and their contact with the tumor cell is a necessary
component of lenalidomide-mediated tumor cell apoptosis (282). Support from Tcells, in the form of IL-2 secretion, is extremely important for NK cell mediated
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cytotoxicity of MM after lenalidomide treatment (271). Although the combination
of lenalidomide with dexamethasone has been shown to have significant activity,
IL-2 production was abrogated in vivo when MM patients received this
combination simultaneously (283). Hsu et al. demonstrated that dexamethasone
treatment suppressed IL-2 production from CD4+ helper T-cells, impaired NK
cell-mediated cytotoxicity and countered the immunostimulatory effects of
lenalidomide in MM patients.

Pharmocodynamic studies may maximize the

efficacy of this combination therapy in MM.
There are multiple mechanisms postulated for increased NK cell killing in
the various disease settings. Both pomalidomide and lenalidomide upregulate the
expression of CD56, which normally decreases NK killing capacity, but in this
setting had no detriment to NK cells (282). Carbone et al. showed that the
expression of natural cytotoxic receptors (NCR) and NK receptor member D of
the lectin-like receptor family (NKG2D) are necessary for myeloma cell
recognition (284) and NKG2D blockade abrogated the effect of lenalidomide in
solid tumors (285). It was recently shown by Benson et al. that the addition of a
murine anti-inhibitory killer immunoglobulin receptor (KIR) antibody with
concurrent lenalidomide therapy mediated rejection of lenalidomide-resistant
tumors in a mouse model (286). This is similar to their IPH2101 human antiinhibitory KIR antibody that also increases in vitro NK cell cytotoxicity specifically
against MM cell targets, but not normal cells, suggesting that clinical testing in
combination with lenalidomide is warranted (286).
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A schematic of the various mechanisms of NK cell-mediated killing in MM
after lenalidomide treatment in combination with various monoclonal antibodies is
shown in (Figure 7). MM cells, like most tumor cells, express the programmed
death receptor-1 ligand (PD-L1) which down-regulates the immune response
against malignant cells through programmed death receptor-1 interactions on Tcells (287, 288). Recently, it was shown that NK cells from MM patients express
PD-1, and the PD-1/PD-L1 interaction decreased NK cell-mediated killing (289).
A novel anti-PD-1 antibody, CT-011, can increase NK cell-mediated killing of
autologous MM cells from patients, without effecting normal cells (289). This new
monoclonal therapy, along with lenalidomide’s action of decreasing PD-L1 on
MM cells, may improve response rates to this combination therapy.
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Figure 7. Lenalidomide alone, or in combination with a variety of
therapeutic monoclonal antibodies, increases NK-cell mediated killing of
multiple myeloma cells. Lenalidomide (LEN) up-regulates Fas expression and
co-stimulatory molecules on MM cells leading to greater Fas-mediated apoptosis.
Len has also been shown to augment the ADCC effect of various monoclonal
antibodies like Rituximab (anti-CD20), GA-101 (glycoengineered anti-CD20), and
CT-011 (anti-PDL-1). CT-011 blocks PD-1 ligand on the MM cells, interfering with
binding to PD-1 and inhibiting NK cell activity. IPH2101 is an anti-inhibitory KIR
that has been shown in combination with len to increase NK-cell killing as well,
as blocking the inhibitory signals allows for NK activation and detection of the
tumor cells.

Enhanced NK-cell ADCC by lenalidomide with combination antibody
therapy. Enhanced antibody dependent cytotoxicity (ADCC) by NK cells is also
an extremely important mechanism in IMiD function in CLL, MM, and even solid
tumors (271, 285, 290). ADCC is a process where antibodies bind to their ligand
antigens on target cells, which then bind to FcR-γ receptors on NK cells, and
trigger cell lysis through perforin and granzyme-dependent pathways (291).
Lenalidomide- and pomalidomide-induced killing via NK cells correlates with an
increase in Fas Ligand (FasL) and granzyme B expression in NK cells, leading to
increased ADCC in multiple tumor settings (290). Thalidomide plus rituximab
(RTX), an anti-CD20 monoclonal antibody commonly used in CLL, was found to
increase complete response rates in relapsed and refractory MCL patients (292).
Further study of the mechanism showed that the drug-antibody combination
increased growth arrest of MCL cell lines, as well as primary cells, compared to
RTX alone (293). Mechanistically, they discovered that lenalidomide enhanced
CD20-mAb-dependent apoptosis of the MCL cells by up-regulating activation of
caspase-3, -8, -9 and the cleavage of PARP, as well as enhanced ADCC by
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CD16 induction on NK cells (293). An increase in NK-mediated ADCC is also
implicated in the success of RTX and lenalidomide combination therapy in CLL
and NHL, although unproven in vivo (294, 295). Ofatumumab, another anti-CD20
monoclonal antibody, binds to a different epitope and induces greater
complement dependent cytotoxicity and has shown evidence of activity in
fludarabine and rituximab-refractory CLL (296, 297). Another CD20 mAb, the
glycoengineered GA-101 antibody, induces greater ADCC in vitro than RTX, and
has shown promising pre-clinical activity in animal models of NHL and B-CLL
(298-302). Lenalidomide therapy is currently being tested with ofatumumab (303)
and elotuzumab (304) in advanced, relapsed or refractory patients, and has
shown therapeutic potential. Therefore, concurrent lenalidomide therapy with
these antibodies may prove beneficial in refractory patients to augment antitumorigenic activity through NK cell potentiating effects.
As an immunomodulatory agent in solid tumors, lenaliomide has been
used to reverse tolerance to tumor antigens (305, 306). As such, lenalidomide
may prove beneficial as an adjuvant to vaccine therapies.

Wu et al.

demonstrated that lenalidomide enhances NK cell killing in a variety of solid
tumor cell lines (breast, colorectal cancer, ovary, head and neck, lung cancer,
bone sarcoma) treated with cetuximab or trastuzumab (285). The treatment of
hematologic and solid tumors with specific monoclonal antibody therapy
concurrently with lenalidomide could potently increase NK cell-mediated tumor
lysis and enhance response rates. Lenalidomide induces NK cells to produce
granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF-α, and
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various immune recruiting chemokines including RANTES, IL-8, MCP-1, and
MIP-1α/β in response to antibody coated tumor cell lines, which contributes to a
more effective immune response (285). The IMiDs enhance immunosurveillance
in solid and liquid tumor settings through recruiting and activating T and NK cells
to suppress malignant growth.
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CHAPTER 2
Reversal of T-cell Tolerance in Myelodysplastic Syndrome through
Lenalidomide Immune Modulation
A note to the reader: This work has been previously published in the journal
Leukemia, McDaniel et al. 2012. (307) and has been reproduced here with
permission from the publisher.
Introduction
Myelodysplastic syndromes (MDS) represent a spectrum of senescencedependent, hematopoietic stem cell disorders (308).

The classical clinical

manifestations include dysplastic cytological features, ineffective hematopoiesis,
and a propensity for transformation into acute myeloid leukemia (AML) (309311). The prognosis varies, but recent FDA approved therapies, such as 5azacytidine and the thalidomide analog lenalidomide, have significantly altered
the natural history of disease (231, 312). In patients with non-del(5q) MDS,
lenalidomide (Revlimid ®, Celgene Inc.) (230)

improves hematopoiesis in a

subset of patients in the absence of the clonal suppression observed in del(5q)
MDS (313). Using micro-array gene expression analysis on bone marrow
specimens from MDS patients treated with lenalidomide, Ebert et al. found that
responsive patients display reduced expression of genes involved in erythroid
differentiation

(238).

Moreover,

treatment

with

lenalidomide

restored

differentiation potential accompanied by up-regulation of the natively suppressed
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erythroid gene signature, indicating that lenalidomide may be effective in a select
subgroup of anemic patients with non-del5q MDS (238).
In addition to its effects on erythropoiesis, lenalidomide is a potent
immunomodulatory

drug

(IMiD®).

All

thalidomide

derivatives

suppress

inflammatory cytokines produced by dendritic cells and activated macrophages,
as well as enhance T and NK-cell proliferation and function (265, 270, 281).
Although the direct erythroid-specific activity of lenalidomide may relate to effects
on erythropoietin (EPO) receptor signaling, little is known about the effect of this
drug and the mechanism of action in vitro and in vivo on the T-cell compartment
(314).

Immune dysregulation plays a critical pathophysiological role in the

pathogenesis of MDS (315, 316), and a subset of low-risk patients with impaired
hematopoiesis experience hematologic improvement after immunosuppressive
therapy with cyclosporine A (CsA) and anti-thymocyte globulin (ATG) (317-319).
T-cells generally lack the del(5q) chromosomal abnormality and are believed to
be derived from the normal lymphoid progenitor compartment. Therefore, the
immune dysregulation in MDS may be driven by activation against the abnormal
myeloid clone. The hematologic remitting activity of lenalidomide in patients with
del(5q) MDS is associated with an increase in bone marrow lymphoid
aggregates, suggesting that activation of these cells may play a role in the
clinical

response

(231).

In

an

effort

to

understand

lenalidomide’s

immunomodulatory activity, and to study the relationship between T-cell function
and hematologic response in MDS patients, we evaluated T-cell activity before
and after lenalidomide treatment, and correlated changes in immune parameters
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with hematologic improvement. The results suggest that lenalidomide-mediated
immunomodulatory function may contribute to hematologic improvement in MDS
lower risk patients, and sheds light on the in vivo mechanism of action.

Results
Characteristics and hematologic response of lenalidomide-treated
MDS cohort. One hundred patients with pathologically defined MDS were
consented at Moffitt Cancer Center to evaluate immune responses. Thirteen of
these were lower-risk, treated with lenalidomide, and had samples collected
before and after treatment. Blood samples from an additional 5 patients with only
lenalidomide pre-treatment samples available were used for in vitro treatment
with lenalidomide, but were not included in the analysis to evaluate the
relationship between T-cell response and hematologic response.

Patient

characteristics and hematologic response to lenalidomide are shown in Table 1.
Seven patients exhibited a major erythroid response out of 13 (53.8%), as
determined by international working group 2000 criteria. The median age of the
group was 74 (range 49 – 83) and the median age of the responders was 72
years (mean 68.3, range 53 – 79 years), which did not differ from the nonresponders (median 78.5, mean 73.5, range 49 - 83) (p = 0.386). Two patients
with del(5q) were treated, one with del(2)(q11.2), one with complex
abnormalities, and the remaining patients had a normal karyotype (n=9). All
patients, including the patients with del(5q), were treated for severe anemia and
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the responsive patients demonstrated a sustained increase in hemoglobin for at
least 4 weeks duration. Patients with del(5q) also had a complete cytogenetic
response with elimination of the clonal myeloid cells. The mean hemoglobin for
the group was 9.1 g/dL, absolute neutrophil count 3.22 x 109 cells/L, and platelet
count was required to be greater than 50,000 cells/L for eligibility on the clinical
trial. There was no difference between responders and non-responders with
regard to international prognostic score (IPSS) or World Health Organization

(WHO) classification.

MDS patient T-cells were inherently tolerant to in vitro stimulation. To
evaluate the proliferative response, the percentage of BrdU positive T-cells after
anti-CD3 antibody-stimulation was compared in healthy donors and MDS patient
PBMCs (n=13). Figure 8A-B shows that the percentage of proliferating T-cells
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(both CD4 and CD8) after stimulation was significantly less in samples from
patients (n=13, 6.91%±3.36) compared to controls (n=27, 17.91%±4.75)
(p<0.0001 for both cell types). The difference in function was age-independent,
as shown in Figures 8A (CD4 Healthy Donor Spearman r=0.009, MDS pt.
r=0.341; both p=ns) and 8B (CD8 Healthy Donor Spearman r=-0.212, MDS pt.
r=0.316; both p=ns), indicating that MDS T-cells are anergic, or hypo-responsive,
to T-cell stimulation.
Incompletely tolerant T-cells can potentially have their proliferative defects
rescued by high doses of exogenous interleukin-2 (IL-2) (320). We therefore
examined the TCR-induced proliferative response of healthy donor and patient Tcells in the presence of anti-CD3 stimulation and anti-CD3 stimulation with 100
U/ml recombinant IL-2. MDS patient T-cells (both CD4 and CD8) had a 57%
recovery of proliferation with the addition of IL-2 in comparison to the normal Tcells stimulated with CD3 alone, but the proliferative capacity was still
significantly below normal levels (data not shown). Also, the proliferation of Tcells in healthy donors and patient T-cells increased with the addition of IL-2, but
the difference between groups remained unchanged (data not shown). This
indicates that T-cells in MDS patients are anergic and only partially responsive to
IL-2.
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Figure 8. T-cells from MDS patients are inherently anergic. Proliferation of Tcells was measured by bromodeoxyuridine (BrdU) incorporation after 2-day
culture in the presence of immobilized anti-CD3 antibody (10 μg/ml). The
percentage of BrdU positive cells was determined in both CD4+ (A) and CD8+ Tcells (B) from 13 MDS patients (MDS) prior to lenalidomide treatment and 28
healthy donors (Controls). A Spearman Correlation was used to determine
correlation of age and % BrdU incorporation, with insignificant p values (A and B,
left). A Wilcoxon rank sum test was used to compare the mean proliferation
between Healthy Donor and MDS patient samples (A and B, right). P-values are
shown. 9 patient samples pre-treatment were used to evaluate capacity to
overcome proliferation defects after stimulation with both immobilized anti-CD3
and recombinant IL-2. The difference between the average of Control vs. MDS
patients was analyzed using Wilcoxon Signed Rank test.

Lenalidomide recovers T-cell proliferation and augments Th1
cytokine production in vitro. Given the T-cell defects observed in MDS, we
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next determined whether lenalidomide increased T-cell responses after culture
with the drug in vitro during stimulation. PBMCs from 18 (untreated) MDS
patients were stimulated in vitro with anti-CD3/CD28 antibodies in the presence
of either 5 μM lenalidomide or vehicle control (DMSO), and proliferation was
determined by BrdU incorporation. Data in Figure 9A shows that culture with
lenalidomide in vitro augments TCR-induced proliferation compared to DMSOtreated cells in both CD4+ (p<0.001) and CD8+ (p<0.001) T-cells, in some cases
up to that of healthy non-treated T-cells (shaded region) (Figure 9A). These
results were compared to unstimulated cells (Unstim) also treated with
lenalidomide. The fact that proliferation was not induced by lenalidomide in the
absence of TCR stimulation indicates that lenalidomide alone has no direct
mitogenic activity (Figure 9A).
In addition to proliferation, in vitro lenalidomide treatment increased
cytokines induced by TCR stimulation, as shown in Figure 9B-C. The cytokine
response favored T-helper 1 (Th1)-type cytokines including interferon-γ (IFN-γ),
tumor necrosis factor-α (TNF-α) and IL-2, which are effectors of anti-tumor
immunity and potentially important for the elimination of pre-malignant or
dysplastic myeloid clones (20). As shown in Figure 9B-C, lenalidomide either
decreased (IL-4) or induced no change (IL-10) in T-helper 2 (Th2) cytokines.
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Figure 9. Lenalidomide augments Th1 type cytokine production and
proliferation in MDS patient T-cells in vitro. MDS patient PBMCs were treated
in vitro with either 5μM lenalidomide or vehicle control (DMSO) for 5 days and
stimulated with anti-CD3/CD28 antibodies. On day 5, an aliquot of cells was
taken and stained for BrdU incorporation in both CD4+ and CD8+ T-cells (A).
The solid line at 17.71 (CD4+) and 17.90 (CD8+) represents the mean
proliferation of untreated healthy donor T-cells. Gray shading indicates the
normal range of one standard deviation above, and one standard deviation below
the mean (A). Also on day 5, cells were stimulated with PMA/Ionomycin for 6
hours, with the last 4 hours in the presence of the protein transport inhibitor
Brefeldin-A (BFA) for intracellular cytokine staining. Flow cytometry was used to
determine the percentage of CD4+ (B) and CD8+ (C) Interferon-γ (IFN-γ), Tumor
Necrosis Factor-α (TNF-α), Interleukin (IL) -2, -4, and -10 secreting cells. The
difference between Len and DMSO treated samples for each patient is shown. A,
B, C. Wilcoxon rank sum test was used to determine statistical difference
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between Len and DMSO treated groups, with DMSO treatment used baseline
proliferation/cytokine secretion; p values are indicated. A Wilcoxon Signed Rank
test was used to determine statistical significance between stimulated and unstimulated samples, A.

Improved homeostatic regulation after lenalidomide treatment in
vivo. Next, the effect of lenalidomide was examined on T-cells in MDS patients
who were treated with lenalidomide in vivo for anemia. The phenotype of T-cells
in the peripheral compartment was examined using the surface markers CD45RA
and L-selectin (CD62L) as phenotypic determinants of distinct naïve and memory
T-cell subpopulations (321-323) with differential functional states. Multicolor flow
cytometry was used to determine the percentage of CD4+ and CD8+ T-cells with
a naïve (N), central memory (CM), effector memory (EM), and terminal effector
memory (TEM) phenotype, and the change in T-cell phenotype (%post – pre)
was then compared in responders (n=7) and non-responders (n=6).

The

percentage of T-cells within each of the memory compartments was compared in
samples that were collected before (pre) and 16 weeks after lenalidomide
therapy (post), as shown in the treatment schematic, Figure 10A.

The flow

cytometry gating strategy is detailed in Figure 10B. The T-cell compartment in
MDS is dominated by EM and TEM T-cells compared to healthy controls, after
adjustment for age (319). Memory phenotype skewing has been previously
reported in MDS and correlated to chronic immune activation in vivo (77). Cells
with the TEM phenotype represent a unique, poorly studied, population of
effector cells that are generally senescent, lack the CD28 co-stimulatory
molecule, and increase through aging and autoimmunity (44, 45).
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Figure 10C

shows that the percentage of naïve CD4 and CD8 T-cells increased significantly
(p=0.004 and p=0.003, respectively), while CD4 and CD8 EM (p=0.046 and
p=0.02, respectively) and TEM (p=0.0032 and p=0.015, respectively) decreased
significantly after lenalidomide therapy. This improved composition within the Tcell compartment was significantly associated with an erythroid response in
MDS. Lenalidomide significantly increased CD8+ CM T-cells (p=0.004, Figure
10C) with a similar trend for increased CD4+ CM cells (p=0.09). The changes in
homeostasis of naïve and memory cells in responders were not due to an overall
increase in total lymphocytes (Figure 11), indicating that lenalidomide alters the
homeostasis of T-cells in the peripheral blood after in vivo therapy in association
with hematologic improvement.
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Figure 10. Naïve T-cells and immune reconstitution after lenalidomide
treatment in hematologic responders. A. Schematic of patient sample
collection and lenalidomide treatment during clinical trial. B. Flow cytometry
gating strategy for memory phenotype on patient PBMCs. Cells were stained for
CD3, CD8, CD45RA, CD62L, and DAPI as a viability marker. Cells were first
gated on DAPI negative, then either CD3+CD8+ (CD8) or CD3+CD8- (CD4).
Memory phenotype of both CD4 and CD8 T-cells was then determined by
CD45RA and CD62L expression, briefly: Naïve (N) cells are defined as
CD45RA+CD62L+, Central memory (CM) are CD45RA-CD62L+, Effector Memory
(EM) are CD45RA-CD62L-, and Terminal Effector Memory (TEM) are
CD45RA+CD62L-. C. The proportion of Naïve, Central Memory, Effector Memory,
and Terminal Effector Memory T-cells for both CD4 and CD8 was determined
using flow cytometry. Naïve cells are described as CD3+CD62L+CD45RA+,
Central Memory as CD3+CD62L+CD45RA-, Effector Memory as CD3+CD62LCD45RA-, and Terminal Effector Memory are described as CD3+CD62LCD45RA+.The difference Post-Pre of each of the phenotypes within Responding
and Non-Responding patients is shown. (R n=7, NR n=6) Statistical analysis was
performed using Wilcoxon Rank Sum. P values are indicated.

Reversal of functional defects in lenalidomide-responsive patients in
vivo. Since lenalidomide is able to alter T-cell homeostasis and reverses
functional T-cell defects in vitro, we assessed the functional impact of
lenalidomide therapy in vivo in CD4 and CD8 T-cells.

For this experiment,

PBMCs were obtained before and after lenalidomide therapy and then stimulated
ex vivo with anti-CD3 antibody to assess their proliferative capacity.

The

proliferative response was determined by the ability to enter S-phase on a single
cell basis using BrdU staining and detection by flow cytometry. The change (%
positive post-pre) in BrdU positive cells after ex vivo stimulation was then
compared among responders and non-responders. Although responders had a
significantly greater proliferative response after therapy compared to nonresponders (Figure 12A, p=0.03 CD4; p=0.004 CD8), this difference was not
associated with an increase in the absolute number of lymphocytes in this cohort
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(Figure 11). The ability of T-cells to produce cytokines was also determined by
intracellular cytokine flow cytometry analysis in responders and non-responders
after ex vivo TCR stimulation with results shown In Figure 12B-C. IL-2 (p=0.05
CD4; p=0.01 CD8), IFN-γ (p=0.03 CD4; p=0.01 CD8), and TNF-α (p=0.004 CD4;
p=0.01 CD8) secreting CD4 (B) and CD8 (C) T-cells were significantly increased
by lenalidomide in responders compared to non-responders. Responders,
however, had either no change or had a decrease in Th2-type cytokines (IL-4
and IL-10) compared to non-responders (Figure 12B-C), indicating that the type
of T-cell immune response is similar to lenalidomide treatment in vitro.

Figure 11: Absolute lymphocyte count remains unchanged during
lenalidomide treatment. Absolute lymphocyte count of Non-Responders (NR)
and Responders (R) at Baseline (pre-treatment), and 1 month intervals during 4
month course of treatment.
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Figure 12. Lenalidomide reverses T-cell tolerance in MDS patients with
hematologic response through increased proliferation and cytokine
production in vivo. A. PBMCs were collected from MDS patients (N=13) prior to
(pre) and 16 weeks after (post) receiving lenalidomide therapy. Patients were
evaluated using the IWG 2000 criteria for response, with 7 responders (R) and 6
non-responders (NR). Cells were cultured in the presence of anti-CD3/CD28
antibodies for 48 hours before measurement of BrdU incorporation. Percentage
of proliferating CD4+ (upper) and CD8+ (lower) T-cells was determined via flow
cytometry. The difference in proliferation (post-pre) was analyzed using Wilcoxon
Rank Sum Test, with p values indicated. B-C. In vivo cytokine production was
determined from the same PBMC patient samples as collected in A for both CD4
(B) and CD8 (C) T-cells. PBMCs were stimulated for 48 hours with CD3/CD28
antibodies, and then for the last 6 hours with PMA/ionomycin. Golgi-block and
cytokine staining was performed as described in Figure 9B.
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Improved

T-cell

homeostasis

is

associated

with

functional

improvement in lenalidomide-responsive patients. Next, the functional
changes in proliferation and cytokine production in MDS T-cells were correlated
with

changes

in

naïve

T-cells

in

patients

treated

with

lenalidomide.

Lenalidomide-induced increases in naïve T-cells was found to positively correlate
with the improved proliferative response observed in both CD4 (p=0.0003) and
CD8 (p=0.0220) T-cells, as shown in Figure 13A. IFN-γ production in CD8 Tcells was also positively correlated with the change in naïve T-cell percentage
(p=0.0118), although this trend was not statistically significant in CD4+ T-cells
(p=0.0941) (Figure 13B). Important to CD4+ T-cell helper function, the increase
in IL-2 production was significantly associated with increased naïve T-cells in
both T-cell subsets (CD4, p=0.0118 and CD8, p=0.0428, respectively).
Collectively, these results suggest that one mechanism for lenalidomide-induced
cytokine production and proliferation is mediated by reconstitution of the naïve Tcell compartment and removal of senescent/hypo-responsive EM and TEM Tcells in those MDS patients with hematologic improvement to lenalidomide.
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Figure 13. Increase in naïve cell production after lenalidomide treatment
correlates with increased proliferation, IL-2, and IFN-γ production. A-C.
MDS patient PBMCs were stimulated as previously described and the
percentage of Naïve CD4+ and CD8+ cells after treatment was compared with
BrdU incorporation (proliferation) (A), Interferon gamma production (B), and
interleukin-2 production (C). Naïve cells were determined as described in 3C. A
trend line was created for both CD4 and CD8 T-cells, and data analyzed via
Spearman correlation. P values are indicated, as well as correlation of the data to
the trend line (Spearman r), with 1 or -1 representing a perfect correlation. NonResponders are represented by an open triangle symbol; Responders are
represented by closed circle.
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The mechanism for increased naive T-cell distribution after
lenalidomide treatment differs in CD4+ and CD8+ T-cells. Thymic involution
limits naïve T-cell output from the thymus and induces a steady decline in naïve
T-cells in the peripheral blood with age (324). Thymic naïve T-cell production
ceases after the age of 65 in humans, so maintenance of the peripheral naïve
compartment rests almost exclusively with homeostatic proliferation (325). To
determine if the lenalidomide-induced increase in naïve T-cells is age related, we
correlated changes in phenotype to age in responders and non-responders. As
shown in Figure 14,

the percentage change in naïve CD4+ T-cells after

lenalidomide treatment in hematologic responders (r=-0.92, p=0.007) showed a
significant negative correlation with age; whereas, the change in naïve CD8+ Tcells was age-independent (Figure 14). These results suggest that naive CD4+
and CD8+ T-cells are differentially regulated by lenalidomide in vivo.

Naïve

CD4+ T-cells may be uniquely increased through an age-dependent release from
the thymus after lenalidomide therapy; whereas, CD8+ T-cells increase through
homeostatic proliferation.
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Figure 14. Naïve T-cell proliferation after lenalidomide treatment correlates
with younger age in hematologic responders. MDS patient PBMCs were
stimulated with antiCD3/antiCD28 antibodies and the percentage of naïve CD4+
(A) and CD8+ (B) T-cells after treatment with lenalidomide in both Responders
and Non-Responders was correlated with age. A trend line was created for both
Responders and Non-Responders in both the CD4+ and CD8+ populations. Data
was analyzed via Spearman correlation. P values are indicated, as well as
correlation of the data to the trend line (Spearman r), with 1 or -1 representing a
perfect correlation. Non-Responders are represented by an open triangle symbol;
Responders are represented by closed circle.

Discussion
The number of patients diagnosed with MDS annually is increasing as a
result of the general trends in population aging (326). It is therefore critical to
delineate response biomarkers and mechanisms of action of FDA approved
therapies such as lenalidomide, to better tailor treatments to individual
pathophysiological mechanisms. High rates of erythroid response in del(5q)
patients are mediated by lenalidomide inhibition of the products of haplodeficient
phosphatases encoded within the chromosome 5q CDR (246) . Nevertheless,
responses in a subset of lower-risk patients lacking the del(5q) abnormality, and
in patients with other hematologic malignancies, indicates that additional
mechanisms may be important (230, 231). We previously reported that
hematologic improvement to lenalidomide is associated with the appearance of
bone marrow lymphoid aggregates, implicating immunologic changes associated
with hematologic response (231). Thalidomide and structural analogues have
potent immunomodulatory effects that are independent of del(5q), with
documented changes in T-cells and NK-cells both in vitro and in vivo in multiple
myeloma and Chronic Lymphocytic Leukemia (CLL) (260, 274, 327).
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The effect of lenalidomide on immune activation in MDS has not been
previously reported. Our current and previous data show that MDS T-cells are
anergic or hyporesponsive to TCR stimulation prior to lenalidomide treatment
compared to T-cells from healthy controls (Figure 8), and only partially
responsive to high-dose exogenous IL-2 (data not shown). After treatment with
lenalidomide in vitro, however, lenalidomide augmented T-cell function, indicating
that the anergy is at least partially reversible and drug responsive. Lenalidomide
is known to increase IL-2 production from T-cells in vitro, mimicking endogenous
IL-2 production (265). In this case, exogenous IL-2 was only partially able to
restore function in these anergic T-cells, suggesting that additional factors may
be involved.
Based on these data, it is possible that lenalidomide directly improves
signaling defects in anergic T-cells or improves immune composition.

Age-

dependent contraction of naïve cells and corresponding accumulation of effector
and terminal effector memory cells (TEM and EM) impairs immune responses in
the elderly (328). A significant improvement in the ratio of naïve-to-memory Tcells was evident in MDS patients with erythropoietic activity, increased cytokine
production, and increased proliferation after lenalidomide in vivo. In responding
patients, lenalidomide was able to reverse the skewed naïve/memory cell ratio by
increasing naïve and central memory T-cells in the peripheral compartment after
therapy, without increasing the total number of lymphocytes (Figure 10C). The
increase in naïve T-cells suggests that lenalidomide preferentially augmented
naïve T-cell homeostatic proliferation, increased thymic output, or a combination
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of both (329, 330). Since new naïve cell production deteriorates gradually over
time as the thymus involutes, homeostatic proliferation becomes the main
avenue for naïve T-cell expansion in the elderly (331-333). CD4+ and CD8+ Tcells differ in homeostatic regulation since CD4+ T-cells are less susceptible to
memory switching than CD8+ T-cells, leading to longer preservation of the naïve
CD4+ T-cell pool over time in healthy individuals (77, 334). Our results indicate
that lenalidomide expands naive CD4+ T-cells through an age-related process
that is greater in younger patients (Figure 14) and expands naïve CD8+ T-cells
through an age-independent process.

To confirm thymic involvement,

examination of T-cell receptor excision circles (TRECs) to identify recent thymic
emigrants is needed.

However, the relationship between lenalidomide and

therapeutic response preference in younger MDS patients has been documented
in a large cohort suggesting that better immune modulation in younger patients
may play a role (335). It is possible that a suboptimal immune response in the
elderly may be an important determinant limiting the activity of lenalidomide in
the aged.
Although there is differential regulation of naïve CD4+ and CD8+ T-cell
subsets, lenalidomide is able to increase the liberation of effector cytokines and
increase proliferation of both T-cell subsets in responders. Our analyses showed
that Th1-type cytokine secretion (Figure 12) was increased in vivo in responders,
suggesting that the effect of lenalidomide on hematopoiesis may be mediated by
eradication of specific abnormal myeloblasts involved in clonal evolution in MDS
(336). In support of this idea, Neuber et al. recently reported enhanced antigen64

specific T-cell activity in vitro and in vivo in multiple myeloma patients, indicating
that lenalidomide has the ability to potentiate tumoricidal activity of effector Tcells (260). Given that MDS T-cells are anergic, and multiple mechanisms are
typically involved in this process, it is possible that lenalidomide improves the
suppressive microenvironment within the bone marrow of MDS patients,
indirectly reversing anergy within the T-cell population. MDS blast cells have
been shown previously to express higher levels of the inhibitory molecule B7-H1
that suppress T-cell proliferation and induce apoptosis of normal T-cells in vitro
(209). Natural CD4+ Tregs, which impair T-cell activation (337), are also
increased in some MDS patients. Therefore, lenalidomide may eliminate the
suppressive populations within the bone marrow, which in turn improves T-cell
responsiveness and acts in concert to restore hematopoiesis in lower risk
responsive MDS patients.
Our findings indicate that hematologic response to lenalidomide is
associated with homeostatic reconstitution and reversal of tolerance in T-cells in
lower-risk MDS patients.

We show that while activation of the immune

compartment occurs after lenalidomide treatment, not all patients re-establish Tcell homeostasis and immune function, or display hematologic improvement after
treatment.

This variability in activity re-iterates the importance of identifying

biomarkers predictive for response to enable more accurate selection of patients
for lenalidomide therapy in non-del(5q) MDS. Our data provides a rationale to
examine a larger cohort of patients to determine if basal T-cell function is
predictive for response to lenalidomide in MDS.
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Materials and Methods
Patients and healthy controls. MDS patients (n=100) were consented
at H. Lee Moffitt Cancer Center in Tampa, FL to participate in a peripheral blood
collection protocol approved by the University of South Florida Institutional
Review Board from 2004-2009. All patients signed University of South Florida
Institutional Review Board-approved informed consents for the collection of 40 ml
of peripheral blood in heparin tubes. Samples were obtained from each patient
at various times from 2004-2009 for immune monitoring studies and all cells were
frozen in liquid nitrogen. Twenty-one of these patients were treated with
lenalidomide, but only 13 patients (Table 1) treated with lenalidomide had
samples obtained both prior to (Pre) and after (Post) therapy. Lenalidomide was
administered at a dose of 10 mg for 21 out of a 28-day cycle for four cycles. In all
patients, the post-treatment sample was drawn after 16 weeks of therapy when
evaluated for hematologic response. Hematologic response was reported
previously within a larger group of MDS patients (338).
Peripheral blood from buffy coats of healthy donors was obtained from the
Southwest Florida Blood Services, St. Petersburg, FL, for use as controls (n=28)
in some experiments. Healthy control T-cells for in vitro experiments were
isolated from buffy coats using RosetteSep® Human CD3+ T-cell Enrichment
Cocktail (StemCell Technologies, Vancouver, BC Canada) according to the
manufacturer’s protocol. Peripheral blood mononuclear cells (PBMCs) were
isolated from patients and healthy donors by Ficoll-Hypaque (Amersham
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Pharmacia Biotech, Piscataway, New Jersey, USA) gradient centrifugation, as
previously described (319).

T -cell activation. To activate the T-cell receptor (TCR), PBMCs were
stimulated with plate-bound anti-CD3 antibody (10 μg/ml) (BD Pharmingen, San
Jose, CA USA) coated onto flat-bottomed polystyrene tissue culture plates
overnight at 4ºC. PBMCs (1 x 106/ml) were added to the coated 96-well plates in
a 200 µl volume for 48 hours at 37ºC. For intracellular cytokine experiments,
soluble anti-CD28 (1μg/ml) (BD Pharmingen, San Jose, CA USA) was added to
provide additional co-stimulation.

Proliferation. Proliferation was determined after in vitro activation by
bromodeoxyuridine (BrdU) incorporation (BrdU flow kit, BD Biosciences, San
Diego, CA).

10 µM of BrdU was added during the last 45 min of T-cell

stimulation. BrdU-pulsed PBMCs were harvested and stained with anti-CD4-PE
and anti-CD8-PE-Cy-5 (BD pharmingen, San Jose, CA USA). The cells were
then fixed and permeabilized with BD Cytofix/Cytoperm buffer and incubated with
DNase for 1 hour at 37ºC. Cells were then stained with anti-BrdU-FITC antibody
before flow cytometry analysis on an LSRII flow cytometer (BD Biosciences, San
Jose, CA USA). The percentage of BrdU positive cells from each population was
analyzed using Flow-Jo Software (BD Biosciences).
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Intracellular cytokine staining. For intracellular cytokine staining in Tcells from MDS patients treated in vivo with lenalidomide, PBMCs from patients
were stimulated on anti-CD3-coated antibody plates (10μg/ml) plus anti-CD28
(1μg/ml) for 6 hours and cytokines were examined by intracellular staining in
gated CD4+ and CD8+ T-cells. Stimulation with anti-CD28 alone was used as a
negative control, and stimulation with PMA (5ng/ml) and ionomycin (250ng/ml)
(BD BioSciences, San Jose, CA USA) was used as a positive control. For
intracellular cytokine staining of MDS patient cells cultured in vitro with
lenalidomide, PBMCs were treated with/without 5μM lenalidomide for 5 days in
the presence of CD3/CD28, as described above. On day 5, they were restimulated with PMA/ionomycin for 6 hours. In both cases, Brefeldin A (10 μg/ml,
Sigma, CA USA) was added during the last 4 hrs of stimulation to block cytokine
secretion. Cells were collected and incubated in EDTA (2 mM final concentration)
for 15 min at room temperature, fixed with 2% formaldehyde for 20 min at room
temperature, and washed with PBS containing bovine serum albumin (BSA).
Cells were permeabilized with FACS permeabilization solution and triple-stained
with CD3-Pe-Cy5, CD8-FITC and intracellular cytokines Interferon- (IFN),
Tumor Necrosis Factor- (TNFα), Interleukin (IL)-2, -4 and -10 (all PE-conjugated
antibodies, BD Biosciences, San Jose, CA USA). Cells were subsequently
washed, re-suspended in staining buffer, and run on a LSRII flow cytometer (BD
Biosciences). Data were analyzed using Flow-Jo Software (BD Immunocytometry
Systems, San Diego, CA). Quadrant markers were positioned to include >99% of
immunoglobulin control stained cells in the negative quadrant.
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Detection of naïve and memory T-cell populations. Naïve and memory
CD4 and CD8 T-cell subtypes were detected after surface staining with anti-CD3PE, anti-CD45RA-FITC, anti-CD62L-APC, and either anti-CD4- or CD8-PECy5
(all from BD Biosciences, San Jose, CA USA). Naïve and memory T-cell
populations were distinguished by CD45RA and CD62L expression, as described
previously by flow cytometry (319, 322, 323); briefly, the memory phenotype
populations are characterized as naïve (CD45RA+/CD62L+), central memory
(CD45RA-/CD62L+), effector memory (CD62L-/CD45RA-), and terminal effector
memory (CD45RA+/CD62L-).

Preparation of lenalidomide for in vitro studies.

Lenalidomide

(Revlimid®) was kindly provided by Celgene Corporation, Warren, NJ. The drug
was weighed and dissolved at the time of use in dimethyl sulfoxide (DMSO) and
diluted 1:1000 in culture media to a final concentration of 5 μM because storage
of stock solutions at

20°C resulted in variable loss in activity. An equal volume

of DMSO was used as a control.

Statistical Analysis. To analyze the difference of paired samples, we
used a Wilcoxon Signed Rank test to determine if the difference significantly
differed from zero. A Wilcoxon Rank Sum test was also used for comparing two
unpaired samples. To assess the relationships between age and the percentage
of cells that were BrdU positive, as well as age and naïve cell percentage,
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Spearman correlation coefficients were calculated.

Relationship between

lenalidomide and DMSO treated in vitro experiments were analyzed using a
student T test. All p values were two sided tests with a significance value of
p<0.05.

70

CHAPTER 3
CD28 expression is required for lenalidomide immune modulation:
identification of a potential mechanism of drug resistance
Introduction
CD28 is a member of the B7 family of T-cell costimulatory molecules that
binds to CD80/CD86 (B7-1/B7-2) expressed on APCs (266, 339, 340). When the
T-cell receptor (TCR) CD3 complex is activated, proliferation can occur, but is
slightly less in the absence of CD28. CD28 receptor co-stimulation, however, is
essential for the induction of interleukin-2 (IL-2) gene expression and for the
prevention of tolerance/anergy within a TCR-activated T-cell population (142,
341-343). CD28 is a transmembrane protein that contains two immuno-tyrosine
activation motifs (ITAMs) within the cytoplasmic tail. Receptor-ligand interaction
induces CD28 homo-dimerization, phosphorylation by src-family kinases lck and
fyn,

and

the

activation

of

downstream

signaling

mediators

including

phosphoinositide 3-kinase (PI3K) and extracellular signal-regulated kinases
(ERK) 1/2 (ERK1/2) (129, 130).

Absence of CD28 co-stimulation has been

implicated in tumor immune evasion and is an important barrier to the success of
tumor vaccine therapy and usually occurs due to B71/2 down-regulation or loss
of CD28 expression(344) .
The necessity of CD28 for IL-2 production has been illustrated using CD28
homozygous deficient (-/-) mice, which lack the ability to induce IL-2 (143) in
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response to antigen stimulation. CD28 is inherently expressed on both CD4+ and
CD8+ T-cell subsets, and increases upon TCR stimulation. Aging of the immune
system in humans, however, is associated with the accumulation of CD28deficient (CD28-, CD28null) T-cells, altering T-cell homeostasis and reducing
pathogen and vaccine immune responses (345, 346). CD28 receptor downregulation results from either chronic TNF-α exposure, as seen in bone marrow
of MDS patients, IL-15 exposure in the absence of TCR ligation, or repeated
TCR engagement indicative of robust proliferative in vivo history (87, 347).
Lenalidomide (LEN) is a second-generation thalidomide analogue with
potent immune-modulating activity approved by the FD for treatment of MDS,
multiple myeloma (MM), and lymphomas. Although known to replace the need
for CD28 external ligation, the mechanism of LEN is poorly understood. The
presence of an interstitial deletion on chromosome 5q (del(5q)) enhances
apoptotic responses of myeloid clones in MDS and improves hematologic
response rates, and approval for LEN in non-del(5q) MDS was issued based on
erythroid improvement in a subset of patients (313).
It is currently unclear if LEN mediates hematologic improvement or antitumor activity in lymphomas, MDS, or MM through immune modulation.

We

previously showed that T-cells from MDS patients are inherently nonresponsive/anergic to stimulation, and secrete less T-cell activating cytokines
(307). Lymphoid aggregates increase in the bone marrow of MDS patients that
improve hematologically, implicating immunologic changes in the response (231).
Our previous findings indicated that patients with erythroid improvement have an
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increase in T-cell proliferation and an increase in IL-2 and Th1 cytokine
production after TCR activation as well as normalization of their naïve:memory
ratio that may contribute to eradication of the myeloid clone (307).
Recently a direct molecular target of LEN was shown to mediate cytokine
production in T-cells (257), but mechanism of LEN co-stimulation through the
CD28 receptor is unknown.

Therefore, the current study was conducted to

determine if LEN requires CD28 expression for IL-2 production in T-cells (339). If
the loss of CD28 renders cells resistant to LEN-induced immune modulation,
then pre-treatment phenotyping for the expression of CD28 may be used as a
biomarker to predict LEN immunomodulatory drug response.

Results
Lenalidomide induces robust interleukin-2 (IL-2) production in the
absence of CD28 co-stimulation. LEN has been shown to enhance proliferation
and IL-2 expression/secretion in T-cells. The expression of IL-2 is completely
dependent upon CD28 activation. To determine if LEN increases IL-2 in the
absence of APCs or without the addition of anti-CD28 antibody, primary purified
CD3+ T-cells were isolated to greater than 95% purity from healthy donors and
stimulated with increasing concentrations of anti-CD3 antibody in the presence or
absence of LEN treatment (Figure 15A). After simulation with plate-bound antiCD3 antibody without ligating CD28, LEN increased the production of IL-2 in a
dose dependent fashion. In contrast, there was little to no IL-2 produced without
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CD28 ligation in cells treated with an equal volume of drug vehicle control
(DMSO). These results indicate that there is a role for CD28 signaling in LEN
immune modulation. LEN treatment was also able to increase, by an average of
6-fold, IL-2 production in T-cells that received both the TCR signal through antiCD3 antibody stimulation plus anti-CD28 (p<0.001, Figure 15B) co-stimulation,
showing that LEN augments the signal initiated by CD28. T-cells were then
stimulated with a fixed dose (5µg/ml) of anti-CD3 alone with increasing
concentrations of LEN to demonstrate the dose-dependency of IL-2 production
(Figure 15C). In addition to protein secretion, we found that LEN enhances IL-2
mRNA expression. A dose-dependent increase in IL-2 mRNA was present in
cells treated with anti-CD3 alone without CD28 after 18 hours compared to
DMSO-treated cells, indicating that LEN transcriptionally activates the IL-2 gene
(Figure 15D).
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Figure 15. Lenalidomide increases IL-2 production in the absence of CD28
external co-ligation. T-cells purified from healthy donor PBMCs were stimulated
in the presence of increasing concentrations of anti-CD3 in the presence of 10μM
lenalidomide (Len) or vehicle control (DMSO). A subset of cells were stimulated
with both anti-CD3+CD28 as a positive control. A-B. IL-2 production was
measured in culture supernatant of cells stimulated with increasing
concentrations of anti-CD3, (A) or anti-CD3+ anti-CD28 (1.0µg/ml) (B) via ELISA.
C. Purified T-cells were stimulated in the presence of 5µg/ml anti-CD3 and
increasing concentrations of Len. D. IL-2 mRNA expression was examined using
RT-qPCR after 18 hours of increasing concentrations of anti-CD3 stimulation. 2way non-parametric ANOVA. *=p<0.05, ***=p<0.001.

Since LEN increases IL-2 gene expression, likely through the CD28
pathway, we determined if LEN augments the binding of a CD28-specific
transcription factor to the IL-2 promoter.

Multiple transcription factors are

required to interact with the IL-2 promoter transcription initiation (Figure 16A).
Some transcription factors are regulated by the TCR signaling cascade, such as
NFAT-1, AP-1, and NF-κB, but these are insufficient for transcription of the IL-2
gene (150). Only binding of transcription factors such as pCREB (a CD28Response Element specific binding factor), NF-κB and AP-1 within the CD28
response element following CD28 receptor ligation is capable of inducing IL-2
transcription. To determine if LEN treatment induces the binding of pCREB to the
IL-2 promoter in the absence of CD28 co-ligation, we performed chromatin
immunoprecipitation (Figure 16A). Results shown in Figure 16B indicate that
with anti-CD3 treatment alone, LEN increases binding of pCREB to the IL-2
promoter compared to DMSO.

These results indicate that LEN specifically

activates the CD28 pathway in conjunction with TCR stimulation.
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Figure 16. CD28 downstream transcriptional element is activated after LEN
treatment. A. Schematic of transcription factor binding sites on the IL-2
promoter. Black arrows indicate forward and reverse primers used in Chromatin
Immunoprecipitation (ChIP) to evaluate pCREB binding to the CD28-Response
Element of the IL-2 promoter. B. pCREB binding to the IL-2 promoter after 18
hours stimulation with 1.0μg/ml anti-CD3 antibody in the presence of vehicle
(DMSO) or 10μM Len treatment. CD3+CD28 stimulation and IgG pull-down were
used as positive and negative controls, respectively. All values were calibrated to
10% input and calculated using ∆∆CT method relative to un-stimulated treated
with DMSO. Graph is representative of 2 replicates. Statistical analysis was
performed using an unpaired T-test. *p<0.05 **p<0.01.

Surface expression of CD28 is increased after LEN treatment upon
TCR activation. Since LEN augments T-cell function through the CD28 pathway,
it is possible that LEN alters CD28 surface expression or recruitment to the
immune synapse. We therefore examined the surface expression of CD28 in
primary T-cells from healthy donors that were either left un-stimulated or
stimulated with anti-CD3 for 3 days (Figure 17). Figure 17A shows a
representative flow plot of CD28 surface expression under these conditions.
Treatment of cells with anti-CD3 in the absence of CD28 co-ligation results in
significant increase in the number of CD28 molecules per cell compared to
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unstimulated cells, as indicated by a shift in median fluorescence intensity (MFI).
After treatment with LEN and anti-CD3, compared to DMSO plus anti-CD3, CD28
surface expression is significantly increased in both CD4 and CD8 LEN-treated
T-cells, suggesting that CD28 expression may be an important determinant of
LEN function (Figure 17A-B).

Figure 17. Surface expression of CD28 is increased after LEN treatment
upon TCR activation. Isolated T-cells were treated with Len or DMSO and
stimulated with polystyrene beads coated with anti-CD3 antibody alone. CD28
surface expression was measured 3 days after stimulation by flow cytometry, and
an example histogram of CD28 surface expression after anti-CD3 stimulation is
shown in A. The black line indicates PE-isotype (negative control), red shaded
region represents un-stimulated T-cells, blue line represents DMSO treated, and
green line is LEN treated T-cells. B. Graphs represent the CD28 MFI in one of
four independent experiments on both CD4+ (left) and CD8+ (right) T-cells. The
difference between Len and DMSO was determined using 2-way non-parametric
ANOVA **=p<0.01, ***=p<0.001. C. CD28 mRNA expression was measured after
18 hours of anti-CD3 stimulation after LEN and DMSO treatment. P values in all
instances are not significant.
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CD28

surface

expression

is

essential

for

LEN-induced

IL-2

production. Ligation of the extracellular portion of the CD28 receptor with antiCD28 antibody cross-linking abolishes CD28 receptor expression through
internalization. Approximately 50% of CD28 is then targeted for degradation in
the endosome while the remainder is recycled back to the surface. For this
reason, surface expression of CD28 was reduced by treating with varying doses
of anti-CD3 in combination with anti-CD28 antibodies to induce receptor
internalization and degradation. Flow cytometry confirmed that CD28 expression,
in the presence or absence of LEN, was significantly reduced after costimulation, with the rate and degree of surface recycling depending on the TCR
signal strength. It was evident that 10 µg/ml of anti-CD3 significantly increased
the rate (24 versus 48 hours) and proportion of cells that re-express CD28
(Figure 18A and B), but this was only slightly increased by treatment with LEN.
To elucidate whether the presence of the CD28 receptor is necessary for
LEN-induced IL-2 production, we purified CD28+ T-cells by flow cytometry
sorting and then subjected them to either CD28 siRNA or control siRNA.
Knocking down CD28 expression in primary T-cells utilizing siRNA is technically
challenging due to the long protein half-life and stable surface expression in the
CD28.

Therefore, we took advantage of receptor degradation in the

experimental design. siRNA-treated cells were compared to siRNA control
(Figure 18)-treated cells after 24 and 48 hours in the presence of 1.0 or 10 µg/ml
of anti-CD3 plus anti-CD28 antibody stimulation. Re-expression of the receptor
was slightly greater in cells treated with a higher dose of anti-CD3 (10 µg/ml
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compared to 1.0 µg/ml) after 72 hours, but siRNA-CD28 treatment significantly
reduced the expression of CD28 in all conditions. An example of the surface
expression of CD28 by flow cytometry in the knockdown experiments is shown in
Figure 18A, and quantified in Figure 18B. Production of IL-2 in LEN or DMSO
treated cells with either siRNA-CD28 knockdown or control siRNA is shown in
Figure 18C. Reduction in CD28 significantly diminished IL-2 and effectively
blocked LEN-induced IL-2 release (decreased from a 7.5-fold increase to 4.9-fold
increase on average compared to control siRNA), as shown in Figure 18C. This
data suggests that the expression of CD28 on the surface imparts response to
LEN.
CD28null cells are resistant to LEN. As described previously, CD28
surface expression is lost on CD8+ memory T-cells as a function of aging, which
contributes to the accumulation of a hypo-responsive CD8+CD28- T-cell
population. The loss of CD28 expression is unique to the CD8 compartment
(348), as there is little or no accumulation of CD4+CD28- T-cells in healthy
individuals. We then determined if LEN could reverse functional defects of
naturally occurring CD28null T-cells. We sorted on CD8+CD28+ and CD8+CD28T-cells from healthy donors, stimulated the cells ex-vivo with anti-CD3 and
examined proliferation and IL-2 production from these two distinct T-cell subsets
(Figure 19A-B). As shown in Figure 19A, LEN increased proliferation of
CD8+CD28+ T-cells in a dose-dependent fashion with anti-CD3 stimulation
alone.

The CD8+CD28- T-cell population displayed an overall significant

reduction in proliferation compared to the CD28+ T-cells, and displayed no
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response to LEN compared to DMSO-treated cells after anti-CD3 stimulation
(Figure 19A). Elaboration of IL-2 was also completely abolished in CD8+CD28T-cells with no response to LEN. These results indicate that the surface
expression of CD28 on T-cells is indispensable for LEN immunomodulatory
response.
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Figure 18. Knockdown of CD28 expression abrogates LEN activity in Tcells. CD28+ T-cells were sorted from healthy donors and transfected with either
non-target (control siRNA) or CD28 siRNA. T-cells were then stimulated with
either 1.0 or 10 μg/ml CD3 and 2.0 μg/ml CD28 for 48 and 72 hours in the
presence of 10μM Lenalidomide or vehicle control (DMSO). A. Example of flow
cytometry plot of one experiment to evaluate CD28 expression after siRNA
infection and plate bound stimulation at 48 and 72 hour time points. Unstimulated T-cells were used as positive control for CD28 expression. B. Bar
graphs (right) quantitatively represent the average %CD28+ T-cells at 48 and 72
hours from 3 independent experiments. C. IL-2 secretion in the supernatant in
cells from A-B was collected after 48 and 72 hours of stimulation and evaluated
by ELISA. B,C) Statistical analysis was performed using 2-Way ANOVA.
**P<0.001 ***P<0.001.

Accumulation of CD28- T-cells in MDS patients is associated with
LEN failure. Although LEN is approved for the treatment of MDS and MM, there
are subsets of patients that are naturally resistant to the drug. Since CD28
expression is essential for LEN immunomodulatory effects in T-cells, we
analyzed CD28 expression on T-cells from MDS patients who were treated with
LEN (Figure 19C-E). Samples were taken before LEN treatment, and the
percentage of CD28 positive cells was compared in responders (R) and nonresponders (NR). Hematologic response was assessed after 16 weeks using
IWG criteria for hematologic improvement. As shown in a representative R and
NR patient (Figure 19C), the percentage of CD28+ cells was greater in the R
compared to the NR. Data on this subgroup of MDS patients (Figure 19D)
indicate that the proportion of CD28 expressing cells pretreatment is significantly
associated with clinical outcome favoring more CD28+ cells in the responders.
Although CD4 T-cells rarely lose CD28 expression in healthy donors, the NR
MDS cohort had a significant accumulation in CD4+ CD28- T-cells (p=0.0061
Figure 19D). A similar significant decrease in the percentage of CD28+ T-cells in
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NR patients was also seen in the CD8 compartment (p=0.0242) (Figure 19E).
This data shows a correlation between accumulation of CD28- T-cells and
resistance to LEN in MDS.

Figure 19. CD28null T-cells are associated with LEN Response. A-B. Healthy
donor CD8 T-cells were sorted into CD28+ and CD28- populations before being
stimulated for 3 days in the presence of increasing concentrations of plate bound
anti-CD3 antibody (μg/ml) in the presence of DMSO (Vehicle) or 10μM
Lenalidomide. A. BrdU incorporation was used to measure proliferation of sorted
CD8+CD28+ and CD8+CD28- T-cells as determined via flow cytometry on day 3.
B. CD8+CD28+, CD8+CD28- T-cells were stimulated as previously described,
and supernatant was collected on day 3 of stimulation. IL-2 secretion was
measured via ELISA. *** p<0.001. MDS patient PBMCs prior to lenalidomide
treatment were analyzed for CD28 expression, and correlated with hematologic
response. C. Representative histograms of CD28 expression on both CD4+ (Left)
and CD8+ (Right) T-cells of erythroid Non-Responders (NR) and Responders
(R). Black shaded region indicates isotype control staining. D-E. Percentage of
CD28+ T-cells from both CD4+ (D) and CD8+ (E) populations was analyzed in 7
NR and 4 R. The difference between the two groups was determined using a
Mann-Whitney T-test with p-values indicated on graphs.
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We have previously shown that MDS patients who respond to LEN
therapy have significant changes in the naive and memory T-cell compartment
after LEN treatment (307). Cells with a CD28- phenotype generally express
CD45RA but lack lymphoid-homing receptors such as CCR7, CD62L, and CD27,
and these terminal effector memory (TEM) cells increase with age and are
associated with autoimmunity (44, 45). The pre-treatment percentage of CD8+
naïve and memory T-cells (central memory, effector memory, and TEM cells)
was then compared in LEN-treated MDS patients and correlated with response
(R verses NR). Figure 20A-C are representative flow plots of CD28 expression
in the different memory phenotypes on T-cells from a healthy donor (Fig. 20A),
Responder (Fig. 20B), and Non-Responder (Fig. 20C). As shown in Figure 20,
there was a clear distinction in the T-cell phenotype based on hematologic
response. CD8+ TEM cells were significantly expanded in NR compared to R
(p=0.02) (Figure 20E), where both naïve and central memory T-cells showed a
tendency toward lower percentages (p=0.06 and =p=0.07). The difference in
TEM CD8+ T-cells also reflects the reduction in the percentage of TEM
expressing CD28 (Figure 20D, p=0.03).

Although CD28-TEM CD8+ T-cells

accumulate with age, the increase in these cells in NR was age-independent, as
shown in Figure 20F. These results indicate that CD28 expression is necessary
for immunologic responsiveness to LEN and loss of CD28 expression of CD8+
and CD4+ T-cells correlates with resistance to LEN in non-del(5q) MDS.
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Figure 20. Non-Responder MDS patients have higher levels of Terminal
Effector Memory (TEM) CD8+ T-cells and lower levels of CD28+ T-cells. The
proportion of Naïve, Central Memory, Effector Memory, and Terminal Effector
Memory T-cells for both CD4 and CD8 from MDS patients treated with
Lenalidomide was determined using flow cytometry. A-C. Phenotype of CD3+
Healthy Donor (A) and MDS Patient Responders (B) and Non-Responders (C)
and CD28 expression within each memory subset. D. Quantification of CD28+ Tcells within the TEM compartment in lenalidomide NR (n=7) and R (n=4) MDS
patients. E. The proportion of each memory phenotype making up the CD8 T-cell
compartment is shown for both Responding and Non-Responding patients prior
to lendalidomide treatment, and is correlated with response after 16 weeks of in
vivo treatment. Statistical analysis was performed using Wilcoxon Rank Sum
Test. F. Proportion of CD8+TEM cells compared with age in MDS Responder (R)
and Non-Responder (NR) patients (p=ns).

84

Discussion
LEN is a highly potent immunomodulatory drug (IMID®) used to potentiate
T-cell and NK cell responses in a number of hematologic and solid malignancies.
Anti-tumor activity of T- cells is increased by stimulating greater production of
cytokines (307, 349), enhancing tumor antigen recognition (260), and activating
T-cells by co-stimulation (265). Antibody-dependent cellular cytotoxicity (ADCC)
(285, 290) and direct induction of tumor cell cytotoxicity (231, 350, 351)
reportedly increases NK cells after LEN treatment. Since LEN enhances the
activity of NK-, T- and B-cells, use of this agent is rapidly increasing in many
settings and the direct molecular target responsible for enhancing immune
function is under intense investigation. We and others have shown that LEN
augments the production of IL-2 in the presence of anti-TCR activation alone
(Figure 15), a function that is closely tied to CD28 signaling. Although LEN may
replace the need for external ligation of the co-stimulatory molecule, we have
demonstrated the requirement for, and the effect of LEN on CD28 surface
expression. Ideally, the role of CD28 should be determined using T-cells from
CD28 knockout mice, as receptor expression would be genetically eliminated,
and these mice have been shown to lack IL-2 transcriptional activation after CD3
antibody stimulation. Unfortunately due to accelerated drug metabolism, altered
pharmacokinetics, or differential regulation of LEN in murine T-cells, this
experiment was not feasible.

To evaluate the role of CD28, a knockdown

approach was used along with evaluation of naturally-occurring CD28 deficient
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cells.

Our data reveal a novel aspect of LEN function and implicates the

expression of the CD28 receptor in the molecular mechanism.
LEN and the thalidomide analog pomalidomide were recently shown to
induce T-cell activation by inhibiting the activation of the E3 Ub ligase cereblon
(CRBN). The function of CRBN in T-cells is undefined (257) and the only known
role of the molecule is in brain and behavioral function.

Casitas-B-lineage

lymphoma protein-b (Cbl-b) and ITCH are RING-finger domain containing E3 Ub
ligases known to regulate CD28 signaling. Cbl-b establishes the threshold for Tcell activation by regulating CD28 and TCRζ recruitment to lipid rafts and
repressing PI3K and Vav1 signaling in the absence of CD28 co-stimulation (158).
The activation of CD28 overcomes the repression by PKCθ-mediated
phosphorylation, which targets Cbl-b for degradation (164). Cbl-b homozygous
deficient mice exhibit lipid raft aggregation, sustained tyrosine phosphorylation of
Vav1 and cytokine production in response to anti-CD3 stimulation without CD28
ligation, similar to LEN treatment (155, 156). Cbl-b -/- mice develop spontaneous
autoimmune-mediated

diabetes,

increased

susceptibility

to

experimental

autoimmune encephalomyelitis, which is a mouse model of multiple sclerosis),
and Cbl-b-null T-cells mediate more efficacious responses to tumors. Our data
suggests that LEN modulate cells similarly to a deficiency in Cbl-b. Whether the
drug can target other E3 Ub ligases or whether CRBN plays and undefined role
in regulating CD28 signaling remains to be determined. It is clear, however, that
LEN does not interfere with CD28 receptor internalization or recycling. CD28,
CTLA4 and ICOS are regulated through receptor endocytosis and trafficking
86

through endosomes and while E3 Ub ligases are known to control receptor
trafficking, their role in CD28 internalization is unknown.
CD28 ligation with CD80/CD86 on APCs in the presence of anti-TCR
ligation enables a fully competent signal response by the T-cells, inducing
cytokine production and proliferation, and preventing anergy (266). Anergy
induction and T-cell non-responsiveness to tumor antigens are major obstacles
to tumor immunotherapy (176). In solid tumors and hematologic malignancies,
there is little expression of co-stimulatory molecules on the tumor cells
themselves, as well as down-regulation of co-stimulatory molecules on DCs
within the tumor environment (352). The lack of co-stimulation induces tolerance
or ignorance by the immune system, preventing tumor-cell detection and
eradication. LEN is being investigated as a combination therapy in a number of
solid and hematologic malignancies due to its co-stimulatory function, while
suppressing Treg expansion (276, 277). LEN’s successes in hematologic
malignancies like B-Chronic Lymphocytic Leukemia (B-CLL), Non-Hodgkin’s
Lymphoma (NHL) and MM are attributed to an immune-mediated anti-tumor
effect, as well as direct anti-tumor activity. Clinical studies in solid malignancies
such as melanoma and ovarian cancer have not demonstrated single-agent
activity, and only nominal survival benefit (353-356). The combination of LEN
with chemotherapy, however, has shown greater activity. For immunotherapy,
benefit of the drug is evident in several solid tumor settings including metastatic
melanoma (357), castration resistant prostate cancer (358, 359), pancreatic
adenocarcinoma (360), and ovarian cancer (361).
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Although LEN has had great successes in MDS and hematologic
malignancies, and has shown potential in a variety of solid tumors, there are still
subsets of patients that do not respond to treatment. Therefore, predictive
biomarkers of response are necessary to help select, prior to therapy, patients
that are likely to respond. We demonstrate in this study that CD28 expression on
T-cells is likely an indicator of LEN responsiveness because of the necessity for
CD28 expression for LEN-induced T-cell function (Figure 18). Augmented
immune function is also implicated in the response of LEN in a subset of low-risk
non-del5q MDS patients (307), and we show here that there is an accumulation
of CD8+ TEM cells prior to LEN treatment in non-responding patients, which are
predominantly CD28null (Figure 20). Hematologic response to LEN in MDS and
MM is likely to involve the immune response (261, 307), and our data indicates
that the accumulation of CD28null T-cells may be a factor in LEN resistance and
suggests that additional clinical studies of biomarker analysis are necessary to
confirm this as a predictive biomarker.
Materials and Methods
Healthy Donor T-cell isolation and activation. Peripheral blood from
buffy coats of healthy donors was obtained from the Southwest Florida Blood
Services, St. Petersburg, FL, for use as controls and for the purification of Tcells. T-cells were isolated from the buffy coats using RosetteSep® Human
CD3+ T-cell Enrichment Cocktail (StemCell Technologies, Vancouver, BC
Canada) according to the manufacturer’s protocol. To activate the T-cell receptor
(TCR), T-cells were stimulated with plate-bound anti-CD3 antibody (1 μg/ml or
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indicated concentration) (BD Biosciences, San Jose, CA USA) coated onto flatbottomed polystyrene tissue culture plates overnight at 4ºC. Purified T-cells (1
x106/ml) were added to the coated 96-well plates in a 200 μl volume for 48 hours
at 37ºC. In some instances, 1.0 µg/ml anti-CD28 was added for co-stimulation.
Stimulation followed by measurement of CD28 surface expression was
performed using anti-CD3 (10 µg/ml) alone or anti-CD3 (10 µg/ml) plus antiCD28 (10µg/ml) coupled 4.5 micron polystyrene polybeads (Polysciences, Inc,
Warrington, PA USA).

1x105 beads were added to 2x105 cells in u-bottom 96-

well plates, as previously described (362). Cells were collected at 72 hours and 5
days, and CD28 surface expression was measured via flow cytometry on LSRII
flow cytometer (BD Biosciences, San Jose, CA USA).
Preparation of lenalidomide for in vitro studies.

Lenalidomide

(Revlimid®) was provided by Celgene Corporation (Warren, NJ). The drug was
weighed and dissolved at the time of use in dimethyl sulfoxide (DMSO) and
diluted 1:1000 in culture media to a final concentration of 10 μM (or indicated
concentration) because storage of stock solutions at

20°C resulted in variable

loss in activity. An equal volume of DMSO was used as a vehicle control.
T-cell Proliferation. Proliferation was determined after in vitro activation
by bromodeoxyuridine (BrdU) incorporation (BrdU flow kit, BD Biosciences, San
Diego, CA USA). 10μM of BrdU was added during the last 45 min of T-cell
stimulation. BrdU pulsed T-cells were harvested and stained with anti-CD4-PE
and anti-CD8-PE-Cy-5 (BD Pharmingen, San Jose, CA USA). The cells were
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then fixed and permeabilized with BD Cytofix/Cytoperm buffer and incubated with
DNase for 1 hour at 37ºC. Cells were stained with anti-BrdU-FITC antibody
before flow cytometry analysis on an LSRII flow cytometer (BD Biosciences, San
Jose, CA USA). The percentage of BrdU positive cells from each population was
analyzed using Flow-Jo Software (TreeStar Inc, Ashland, OR USA.).
Cell Sorting. T-cells were purified from healthy donor buffy coats as
previously described, and were stained with 4',6-diamidino-2-phenylindole (DAPI)
for viability, anti-CD8-APC-Cy7, CD4-PerCP-Cy5.5, and CD28-FITC antibodies
(BD Pharmingen, San Jose, CA). Cells were then sorted into CD8+CD28+,
CD8+CD28- populations via FACS Aria Cell Sorter (BD Pharmingen, San Jose,
CA).
siRNA Transfection and ELISA. For siRNA knockdown (KD), T-cells
were transfected with siCD28 or control siRNA (Santa Cruz Biotechnology, Inc,
Santa Cruz, CA USA) using Amaxa Nucleofection technology (Lonza, Basel,
Switzerland). 10x106 purified T-cells were mixed with either control or
CD28siRNA in 100μl Human T-cell nucleofection solution, nucleofected, and then
placed in Lymphocye Media (Lonza Basel, Switzerland). Cells were rested 24
hours before being stimulated with either plate bound anti-CD3, or antiCD3+CD28, antibodies in the presence or absence of lenalidomide. CD28
surface expression was measured via flow cytometry at 48 and 72 hours after
stimulation, at the same time supernatant was collected for ELISA analysis.
Supernatant from stimulation experiments was frozen at -80ºC for analysis via
Human IL-2 ELISA kit (eBioscience, San Diego, CA USA).
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RT-qPCR. Total RNA was extracted from purified T-cells using the
RNeasy Mini Kit (Qiagen, Chatsworth, CA USA).

Reverse transcription was

performed using the iScript cDNA synthesis kit (Biorad, Inc. Hercules, CA USA)
in accordance with the manufacturer’s suggestions. Relative target gene
expression was measured by qRT-PCR using 18S rRNA expression as a
reference gene. Expression levels of target mRNA and 18S rRNA were
evaluated with Taqman Probes obtained from Applied Biosystems (Carlsbad,
CA). All samples for both target genes (IL-2 or CD28) and 18S rRNA were
measured in triplicate. Relative mRNA expression level for each sample was
calculated using the ∆∆Ct method (363).
Chromatin Immunoprecipitation (ChIP). Cells were isolated, fixed,
lysed, and sonicated before chromatin-immunoprecipitation, as previously
described (364). Briefly, after stimulation and drug treatment, primary T-cells
were treated with 1% formaldehyde for 10min for cross-linking, followed by cell
and nuclear lysis (50 mM Tris, pH 8.1, 10 mM EDTA, 1% SDS, 0.5 mM PMSF)
and shearing. Chromatin was immunoprecipitated using 5µg anti-phospho-CREB
antibody (Millipore, Temecula, CA USA) and protein A/G beads (Santa Cruz
Biotechnology Inc., Santa Cruz, CA USA). Immunoprecipitated chromatin was
collected and washed sequentially with TSE buffer (20mM Tris, pH 8.1, 50mM
NaCl, 2mM EDTA, 0.1% SDS, 1.0% Triton X-100) and LiCl buffer (100mM Tris,
pH 8.1, 50mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholic acid, 1mM EDTA).
DNA was then eluted from the beads with 50 mM NaHCO3 containing 1% SDS
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and cross-linking reversed at 65°C overnight followed by proteinase K treatment.
DNA was then purified via QIAquick PCR purification kit (Qiagen, Germantown,
MD USA). For each sample, 4µl DNA was amplified and measured using Sybr
Green (Bio-Rad, Inc., Hercules, CA USA). Primers used to amplify the pCREB
binding site -180 upstream of the transcription start site were: forward: 5’AGAAGGCGTTAATTGCATGAATT-3’

and

reverse:

5’-

TCCTCTTCTGATGACTCTTTGGA-3’.
MDS Patient Samples. MDS patients (n=100) were consented at H. Lee
Moffitt Cancer Center in Tampa, FL to participate in a peripheral blood collection
protocol approved by the University of South Florida Institutional Review Board
from 2004-2009. All patients signed University of South Florida Institutional
Review Board approved informed consents for the collection of 40 ml of
peripheral blood in heparin tubes. Samples were obtained from each patient at
various times from 2004-2009 for immune monitoring studies and all cells were
frozen in liquid nitrogen. Twenty-one of these patients had samples that were
collected within 4 weeks prior to LEN treatment. LEN was administered at a dose
of 10 mg for 21 out of a 28-day cycle for four cycles. All patients were evaluated
for hematologic response after 16 weeks according to 2006 International Working
Group Criteria (IWG). Hematologic response was reported previously within a
larger cohort of MDS patients (338).

92

Analysis of T-cell naïve and memory populations. Naïve and memory
CD4 and CD8 T-cell subtypes in MDS patients and healthy donors were detected
after surface staining with anti-CD3-PE-Cy7, anti-CD8-PerCP-Cy5.5, antiCD45RA-FITC, anti-CD27-APC, anti-CD28-PE, and DAPI (all from BD
Biosciences, San Jose, CA USA). Naïve and memory T-cell populations were
distinguished by CD45RA and CD27 expression, as described previously by flow
cytometry (319, 322, 323); briefly, the memory phenotype populations are
characterized as naïve (CD45RA+/CD27+), central memory (CD45RA-/CD27+),
effector

memory

(CD27-/CD45RA-),

and

terminal

effector

memory

(CD45RA+/CD27-). Samples were run on an LSRII flow cytometer (BD
Pharmingen) and populations were analyzed by FlowJo Software (Tree Star Inc.,
Ashland, OR USA).
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CHAPTER 4
Lenalidomide and the IMiDs inhibit the negative regulatory activity of
protein phosphatase 2A in T-cells to mediate T-cell co-stimulation
Introduction
Thalidomide is a potent immunomodulatory drug (IMiD) with antiangiogenic and anti-TNF-α effects, as well as immune stimulating properties
(222, 223). Although thalidomide was discovered to be a potentially important
anti-cancer agent, severe side effects led to the development of the thalidomide
analogues lenalidomide and pomalidomide, with greater immunomodulatory
activity and less side effects such as peripheral neuropathy (227, 229). In 2005,
lenalidomide was approved for the treatment of del(5q) myelodysplastic
syndrome (MDS) because of its ability to induce karotype-specific transfusion
independence and cytogenetic response (230). Isolated del(5q) MDS occurs in
less than 15% of MDS cases where there is a 3 megabase (Mb) interstitial
deletion on the long arm of chromosome 5 (5q31-5q32) coined the commonly
deleted region (CDR) (365, 366). Patients with this specific chromosomal
abnormality have a lower risk for leukemia transformation, improved survival, and
a 75% complete response rate to lenalidomide treatment compared to other MDS
patients without the deletion (230, 233). MDS is a clonotypic heterogeneous
grouping of diseases characterized by ineffective hematopoiesis, multiple
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cytopenias, dysplasia in the myeloid lineage, and a high risk for transformation to
acute myeloid leukemia (AML).
Although lenalidomide is able to induce high rates of transfusion
independence in a subset of MDS patients without del(5q), the mechanism of
action of the drug in inducing apoptosis of the del(5q) myeloid clone and
improving hematopoiesis is still unclear due to the complexity of the disease.
Ribosomal abnormalities have been implicated in the pathogenesis of MDS,
namely a loss of RPS14 gene expression, located within the 5q-CDR. Deletion of
this gene through an siRNA screen was shown to be sufficient to induce the
del(5q)-associated pattern of impaired hematopoiesis and the del(5q) syndrome
in mice(239, 240). RPS14 loss, or inhibition of ribosomal processing proteins
leads to nucleolar stress, degradation of murine double minute protein 2 (MDM2)
and increased p53 expression in the erythroid blasts, subsequently increasing
the expression of p53 target genes (like p21) that prevent cell cycle progression
and induce apoptosis (241, 242). Wei and colleagues have recently
demonstrated that lenalidomide can promote p53 degradation within the erythroid
blasts through inhibition of the auto-ubiquitination of MDM2, allowing MDM2 to
ubiquitinate p53 and induce its degradation (243).
Although these results suggest a mechanism for lenalidomide in
promoting erythropoiesis, our group has shown that another set of genes within
the CDR may be targeted by lenalidomide to induce myeloid apoptosis. Our
group has shown that lenalidomide may inhibit the activity of the haplodeficient
phosphatases cell division cycle 25c (Cdc25c) and protein phosphatase 2A
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(PP2A) to prevent cell cycle progression and induce apoptosis within the myeloid
clone (246). Reduction in phosphastase expression through siRNA in non-del(5q)
MDS patient cell lines was sufficient to render them susceptible to lenalidomideinduced apoptosis through direct and indirect mechanisms. PP2A is a
heterotrimeric, ubiquitously expressed serine/threonine phosphatase involved in
a myriad of cellular processes, including cell cycle regulation, signal transduction,
cytoskeleton dynamics, and cell mobility (165, 166).
Although lenalidomide may increase erythropoiesis and induce apoptosis
within the del(5q) clone, the importance of immune activation against the myeloid
clone has also been implicated in lenalidomide’s mechanism of action in MDS.
Lenalidomide has previously been shown to have potent immune stimulatory
activity, likely through activation of the T-cell co-stimulatory pathway (265). The
activation of immune system seems to be important in MDS patient response to
lenalidomide treatment, as patients who responded to lenalidomide have an
increase in immune infiltrates into the bone marrow (230), and increased T-cell
proliferation and cytokine production in vivo (307). The immunomodulatory
activity is also implicated in multiple myeloma and chronic lymphocytic leukemia
(253, 260). Interestingly, PP2Acα is a key negative regulator of the CD28 costimulatory pathway in T-cells, reversing lck-induced phosphorylation of the
cytoplasmic tail of the receptor (174). PP2A overexpression is implicated in
decreased interleukin-2 (IL-2) production in systemic lupus erythematous (SLE)
patients through increased de-phosphorylation of the pCREB transcription factor
and carma-1 signaling molecule (171, 172). Lenalidomide has been shown to
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increase phosphorylation of CD28 and secretion of IL-2 after anti-CD3
stimulation alone (270), alluding to the inhibition of a negative regulator of T-cell
signaling in the drugs immune modulatory mechanism.
Therefore, we utilized multiple approaches to evaluate the interaction
between PP2A and lenalidomide immune modulation. Both functional studies
and molecular modeling approaches were used to evaluate the molecular
mechanism of lenalidomide-induced T-cell proliferation related to PP2A inhibition.

Results
PP2A activity in T-cell lines and primary T-cells is inhibited with
lenalidomide treatment.
PP2A is a negative regulator of IL-2 production through direct dephosphorylation of the CD28 receptor, as well as de-phosphorylating and
therefore inactivating several downstream signaling factors including CREB and
CARMA-1 (171, 172). Both lenalidomide and pomalidomide are able to increase
IL-2 production from primary T-cells stimulated with anti-CD3 antibody alone, in
the absence of anti-CD28, although lower amounts of IL-2 are induced by
thalidomide even when higher doses are used (0.05µg/ml POM and LEN versus
1.0 µg/ml THAL). It was evident that all three drugs significantly increase IL-2
production compared to DMSO vehicle-control treated cells (Figure 21 A).
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Figure 21. Lenalidomide increases IL-2 production and inhibits
phosphatase activity of PP2A isolated from Jurkat and primary T-cells. A.
All three IMiDs induce IL-2 production from primary T-cells with increasing doses
of anti-CD3 stimulation relative to DMSO control measured by ELISA. Data
analyzed using 2-Way ANOVA: **=p<0.01, ***=p<0.001. B-C. Measurement of
endogenous PP2Ac activity from T-cells. PP2Ac was immunoprecipitated from
cells treated with either DMSO (vehicle) or Len. Free phosphate released was
then measured via phosphatase activity assay. Western blot in both A and B
(upper panels) show equal pull-down of PP2Ac in each sample to ensure
changes in activity were not due to unequal PP2Ac loading. IgG was used in
each case as a negative control. A. PP2Ac catalytic activity was decreased in
Jurkat cells treated with Len, p-value is indicated. B. PP2Ac activity from primary
T-cells treated with len and stimulated in vitro with anti-CD3 antibody for 15
minutes was decreased compared to DMSO control. ***=p<0.001.
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Although we have previously shown that lenalidomide can inhibit PP2A
activity, it is unclear whether this occurs in primary T-cells. To analyze this,
Jurkat T-cells and primary T-cells isolated from a healthy donor were treated with
lenalidomide, PP2Ac was immunoprecipitated and subjected to an in vitro
phosphatase activity assay. Figure 21B shows that lenalidomide can inhibit
PP2Ac activity in Jurkat cells. The same can also be seen in primary T-cells after
stimulation with anti-CD3 antibody (Figure 21C). These data indicate that
lenalidomide inhibits PP2A phosphatase activity in T-cells after anti-CD3
activation, and this decrease in activity is associated with the release of IL-2.
PP2A catalytic activity is inhibited after in vitro treatment with the
IMiDs. Although it was previously shown that lenalidomide can induce apoptosis
of the del(5q) clone when PP2Ac expression is reduced, the ability of
lenalidomide to inhibit PP2A catalytic activity was not established. To first
determine if lenalidomide inhibits the catalytic activity of PP2A, ad293 cells were
stably transfected with HA-tagged PP2Ac and treated with lenalidomide. After
lenalidomide treatment, PP2Ac was immunoprecipitated and subjected to in vitro
phosphatase enzymatic activity assay. As shown in Figure 22A, treatment with
increasing concentrations of lenalidomide resulted in a dose-dependent decrease
in PP2Ac enzymatic activity compared to DMSO vehicle control. Western blot
analysis was performed to ensure equal HA-PP2Ac protein was present in each
sample.
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Since lenalidomide is able to inhibit PP2A enzymatic activity in vitro, we
next determined whether other IMiDs display similar inhibitory function. Figure
22B-D shows that all three of the IMiDs, to varying degrees, inhibit PP2Ac
phosphatase activity in a dose-dependent manner, with thalidomide being the
least potent (Figure 22D). Figure 22E compares the percent activity of the PP2A
enzyme in the presence of 10µM of the IMiDs, demonstrating that lenalidomide
and pomalidomide are more potent inhibitors than thalidomide. This is consistent
with the relative immunomodulatory effects of thalidomide and the various
derivatives.
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Figure 22. PP2A catalytic activity is inhibited after in vitro treatment with all
of the IMiDs. A. For phosphatase activity assay, human embryonic kidney (HEK)
cell line was stably transfected with Hemagluttinin (HA)-tagged PP2Acα. HAPP2Ac was immunoprecipitated from ad293 cellular extracts treated with vehicle
(DMSO) or 5-10µM lenalidomide (Len). Upper panel western blot shows equal
pull-down of HA-PP2Ac in HA-transfected cells, and no pull-down in empty vector
transfected (EV) and IgG pull-down negative controls. Graph represents dosedependent decrease in free-phosphate released through PP2A activity with
increasing doses of lenalidomide treatment. B-E. HA-PP2Acα expressing-HEK
cells were treated with varying doses of IMiDs before HA-PP2A was then
immunoprecipitated (IP), incubated with phospho-threonine peptide and
phosphatase activity measured by Malachite green assay. Dose dependent
inhibition of PP2Ac activity can be seen with lenalidomide (B) and pomalidomide
(C). Inhibition of PP2A activity is seen at highest thalidomide dose (D). E. Graph
represents inhibition of PP2A activity at 10μM dose of all three IMiDs. T-test: *= p
0.0002 **= p<0.0001.

Virtual computer modeling reveals a potential direct interaction of
the IMiDs within the active site of the PP2A catalytic subunit. Recently,
cereblon (CRBN) was shown to directly interact with IMiDs and to suppress its
auto-E3-ubiquitination function.

This is the only molecule known to directly

interact with IMiDs. Next, we used a molecular computer modeling approach to
estimate the potential for lenalidomide and the other IMiDs to directly bind to
PP2A. Four compounds were prepared for docking to PDB 3K7V: lenalidomide,
pomalidomide, thalidomide, and a known potent PP2Ac inhibitor, fostriecin. Each
of

these

compounds

possesses

chiral

carbons,

therefore

alternative

stereoisomers were included in the docking. All of the IMiDs are administered as
a racemic mixture, and cannot be administered in isolation as they can freely
transform in vivo (219). Both the R and S forms of lenalidomide place the
nitrogen bearing six-membered ring into the hydrophobic region of the binding
site, and bind with similar estimated free energies of -6.52 and -5.80,
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respectively. The R and S forms of pomalidomide actually dock significantly
differently from one another, but have nearly identical docking energies (-6.39
and -6.06). The R and S forms of thalidomide binds similarly to thalidomide and
lenalidomide , although the chirality causes significant differences in estimated
binding free energy. The S enantiomer dockings of the IMiDs are shown in
Figure 23A-C. As you can see, lenalidomide (Figure 23A) and pomalidomide
(Figure 23B) form 2 hydrogen bonds within the catalytic pocket of the c-subunit;
lenalidomide creates a hydrogen bond to W200 and R214 and pomalidomide to
R214 and S120. The S binding pose of thalidomide on the other hand, only forms
one hydrogen bond within the pocket, at W200, (Figure 23C) suggesting that the
racemic mixture of the R and S forms of thalidomide would have significantly
reduced binding capacity compared to the racemic mixtures of len and pom.
Fostriecin is a significantly more potent and specific inhibitor of PP2A enzymatic
activity and is effective in the nanomolar concentrations (367). The binding free
energy for fostriecin was -9.17 kcal/mol and it was capable of making three
hydrogen bonds, supporting the validity of the docking experiments. Further
validation of the docking site can be seen through published co-crystallization of
another PP2Ac inhibitor, okadaic acid, within the catalytic pocket of PP2A.
Okadaic acid also shares all three potential interaction sites, H191, W200, and
R214, within the PP2A active site (368). These data support the in vitro data that
thalidomide is the weakest inhibitor of PP2A enzymatic activity, and suggest a
potential direct inhibition of PP2A enzymatic activity in T-cells.
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Figure 23. Virtual modeling of the IMiDs reveals potential interacting sites
within the catalytic pocket of the PP2Ac subunit. Free energies of binding
and poses for the molecules suggest that both the R and S enantiomers of all
three immunomodulatory drugs bind to the same position within the catalytic
pocket of the c subunit of the PP2A heterodimer, and thereby possibly inhibit
phosphatase activity (A-C). The S enantiomers of both lenalidomide (A) and
pomalidomide (B) have better binding poses and energies (-5.80 kcal/mol and 6.06 kcal/mol respectively) than thalidomide (C) (-5.34kcal/mol). S enantiomers
of IMiDs Lenalidomide (A), Pomalidomide (B), and Thalidomide (C), are shown
bound within the catalytic pocket of PP2Acα. Dashed lines indicate hydrogen
bonds between the small molecule inhibitors and amino acid residues W200 and
R214. Another hydrophobic interaction is shown to occur at H191. Black oval (C)
indicates position where thalidomide lacks second hydrogen bond compared to
the other compounds, owing to the lack of aromatic amine group seen in A.

Mutations in the lenalidomide-binding sites of the PP2A catalytic
subunit render PP2A enzymatically inactive. Since virtual modeling predicted
potential binding sites for lenaliodmide within the catalytic pocket of PP2A, it is
possible that lenalidomide could directly bind to the active site and inhibit PP2A
enzymatic activity. To confirm this prediction, we utilized site-directed
mutagenesis of the estimated interaction sites that may be required for
lenalidomide-mediated PP2A inhibition. According to the virtual modeling
predictions, aaW200 and aaR214 may be important binding sites for
lenalidomide within the PP2A catalytic pocket, forming a hydrogen bond with the
lenalidomide S molecule. H191 was also implicated in lenalidomide binding
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through formation of a hydrophobic interaction with the six-membered ring.
These three amino acids in PP2Ac were mutated using site-directed
mutagenesis and overexpressed in ad293 cells. As shown in Figure 2, a similar
immunoprecipitation approach was used to selectively evaluate the function of
the mutant proteins using immunoprecipitation with anti-HA antibody (IP anti-HAPP2Ac).

Stable cell lines of the HA-WT (wild-type) and HA-PP2Ac mutant

proteins were established. Figure 24A shows the phosphatase activity and
cellular expression of the different clones. WT-HA PP2A was used as the positive
control (100% activity). Clones expressing W200F-D, R214A, and H191G did not
retain HA-plasmid expression after selection, and therefore could not be utilized.
Three independent W200F (A-C) and R214A (B-D) clones expressed mutated
HA-PP2Ac protein but had no enzymatic activity, indicating that mutation of these
amino acids renders PP2A catalytically inactive revealing novel amino acids
within PP2A critical for function. Due to the importance of these amino acids in
PP2A function, these mutant constructs were not useful to evaluate the effects of
lenalidomide.
The only mutated clone retaining PP2A enzymatic activity was H191G-B,
which was then utilized in lenalidomide experiments. Lenalidomide as well as an
independent PP2A inhibitor (okadiac acid, OA) retained their suppressive
function in the presence of the mutation (Figure 24B; p<0.001). Therefore, these
mutant PP2A proteins cannot conclusively determine whether the direct
interaction between lenalidomide and PP2A is important for the suppressive
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response, although we have identified novel amino acids involved in the catalytic
function of PP2A.

Figure 24. Mutations of theorized IMiD-interacting sites alters PP2A
enzymatic activity. Virtual modeling suggested three potential amino acids
within the catalytic pocket of PP2A to interact with lenalidomide. Mutations in
these sites (W200F, R214A, and H191G) were created and the effect on the
enzymatic activity of PP2A (A) and of lenalidomide’s ability to alter PP2Ac
enzymatic activity (B) were analyzed. A. WT-PP2Ac and mutants were
immunoprecipitated from ad293 cells using anti-HA tag antibody and subjected to
phosphatase activity assay. Red box highlights clones with no catalytic activity.
One clone, H191G-B did retain enzymatic activity. Western blot (upper panel) of
HA-PP2Ac expression used as positive indicator of mutant protein expression. B.
H191G-B retained enzymatic activity, and was subjected to lenalidomide
treatment and subsequent phosphatase activity assay. Mutation of histidine 191
to glutamate did not alter lenalidomide’s ability to inhibit PP2Ac activity analyzed
by 2-way ANOVA. **=p<0.01, ***=p<0.001.

Discussion
Lenalidomide and the other IMiDs are known to augment the proliferation
and function of T-cells and NK cells by a mechanism that involves CD28
signaling and possibly involves suppression of CRBN. Previous work has shown
that lenalidomide specificity for apoptosis induction in MDS del(5q) is mediated
by haploinsufficiency of PP2Ac and Cdc25c.
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Reduction in these two

phosphatases alone are sufficient to render resistant myeloid clones susceptible
to lenalidomide-induced apoptosis as shown by shRNA knockdown of these
molecules in non-del(5q) hematopoietic progenitors and cell lines(246). Although
these proteins are important cell cycle regulators, PP2Ac is essential to many
cellular processes, including negative regulation of CD28 co-stimulatory signaling
in activated T-cells. Previous studies in our lab have shown that lenalidomide
treatment increases pCREB binding to the IL-2 promoter (307).

PP2A can

directly de-phosphorylate Carma-1, subsequently dissociating it from the CBM
complex (172). Therefore, it is plausible that lenalidomide may stimulate IL-2 by
inhibiting this negative regulator of T-cell signaling. Since CD28 stimulation is
needed for de-phosphorylation of Carma-1, activation of this pathway may be
mediated directly by lenalidomide leading to increased and prolonged signaling
for proliferation and cytokine secretion in the absence of CD28 co-stimulatory
ligation.
We have demonstrated through in vitro phosphatase activity assays that
lenalidomide and the other IMiDs, to varying degrees, can inhibit PP2Ac
enzymatic activity (Figures 21-23). Based on previous experiments, lenalidomide
has no direct inhibition of PP2Ac phosphatase activity. There are several
plausible explanations, namely lack of proper PP2Ac subunit folding in
baculovirus-generated

protein,

or

improper

PP2Ac

holoenzyme

subunit

formation. It is difficult to generate properly-folded recombinant PP2Ac protein,
as the catalytic subunit generated in bacteria is non-functional. Therefore, it is
plausible that commercially available recombinant PP2A protein is altered in
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confirmation compared to in vivo-expressed protein, and therefore lenalidomide
cannot bind. Another plausible explanation is that the recombinant protein comes
as an A-B-C heterotrimer with a fixed beta subunit. PP2Ac is a heterotrimeric
enzyme composed of a scaffolding subunit (A α or β) , a catalytic subunit (Cα or
β) and one of 16 different B-regulatory subunits (B, B’, B’’, or B’’’ family) with
variable expression based on cell and tissue type (165, 166, 369). The A-C core
enzyme has been purified from many different tissues, but its presence in vivo is
slightly controversial and specific substrates of the dimer alone have not been
identified (370). Since PP2A is ubiquitously expressed and involved in a myriad
of cellular processes, that A-C heterodimer binds to the multiple different Bregulatory subunits that confer substrate specificity and prevent random dephosphorylation activity of the PP2A enzyme (167, 371-373). The B subunit
expressed with the PP2Ac heterotrimer in recombinant protein may not allow for
proper lenalidomide binding to allow inhibition of enzymatic activity. Proteomics
analysis of immunoprecipitated protein from lenalidomide treated lysates was
unable to identify a particular ratio of B subunits distinct to lenalidomide-binding
(data not shown).
Therefore, a molecular modeling approach was used to theoretically
indicate the potential for lenalidomide direct binding interactions with PP2A, and
found that all three of the IMiDs can potentially bind within the catalytic active site
of the PP2A catalytic subunit in both the R and S enantiomeric forms (Figure
23). It was important to include both of the racemates in the virtual analysis, as it
has been previously postulated that different forms of thalidomide (and
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subsequently lenalidomide) have different in vivo activities (218, 219). Also,
stereochemistry in virtual screening has been previously determined to
significantly affect free binding energies (374). Interestingly, the lenalidomide
racemates bound with similar docking poses and binding energies, while the
thalidomide R and S enantiomers had dramatically different docking poses, with
the S form of thalidomide losing a hydrogen bond within the pocket, reducing its
binding energy. These results, combined with the expected higher binding energy
of the known specific and potent PP2A inhibitor, forstriecin, indicate that it is
possible for the IMiDs to directly bind to the PP2A active site to inhibit
phosphatase activity.
To validate these predictions, mutation in the predicted interacting
residues were made by site-directed mutagenesis, stably over-expressed, and
tested for phosphatase activity. Mutation of only one of the potential interacting
residues produced a functional protein.

The other mutants either induced

apoptosis or rendered the enzyme catalytically dead.

Although this virtual

modeling revealed novel amino acids with importance for PP2A catalytic function,
the mutant proteins were unable to yield information about the nature of
lenalidomide function. The only mutation to retain activity was H191G, which was
predicted to generate only Van der Waals interaction with the lenalidomide
compound, and mutation of this site failed to disrupt lenalidomide, OA, or
fostriecin function.
Suppression of PP2A with lenalidomide in T-cells was evident only after
anti-CD3 activation which is more consistent with an indirect mechanism of
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suppression. Although proof of direct inhibition of PP2A phosphatase activity was
not established, either direct or indirect inhibition of PP2A by lenalidomide and
the other IMiDs is important for establishing the molecular mechanism of action
of IMiDs in T-cells. Several other proteins such as E3 ubiquitin ligases murine
double minute 2 (MDM2) and CRBN have recently been implicated as direct
lenalidomide targets in MDS erythroblasts and multiple myeloma (243, 256, 257).
The role of CRBN in T-cell proliferation and activation is unclear. Knockdown of
CRBN expression in T-cells was shown to abrogate lenalidomide’s cytokinepromoting activity, leading to the idea that CRBN expression is essential for
lenalidomide’s mechanism of action (257) but functional studies of CRBN in Tcells are lacking. Currently, the only E3 ubiquitin ligase known to regulate the
response of CD28 is Cbl-b. More studies are necessary to confirm the role CRBN
in PP2A function, Cbl-b, and CD28 signaling during T-cell activation.

Materials and Methods
Cell culture and creation of stably transfected cell lines. Ad293 cells
were cultured in RPMI 1640 media (Gibco, Life Technologies, Grand Island, NY,
USA) supplemented with 10% heat-inactivated FBS without antibiotic. Cells were
transferred to 6-well plates at concentration of 0.8x106 cells/well in 2ml media.
The next day, each well was transfected with 4μg plasmid DNA pcDNA3 vector
containing HA-PP2Acα, or empty vector, using Lipofectamine 2000 (Invitrogen,
Grand Island, NY USA) according to the manufacturer’s protocol for adherent
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cells. 48 hours later, stably transfected cells were selected for using media
supplemented with 1.0mg/ml G418 Sulfate (Cellgro, Manassas, VA USA). Cells
were then diluted to 1 cell/well in a 96-well plate to isolate single clones
expressing either HA-PP2Acα or empty vector. Stable expression of the HA
transgenic protein was determined via western blot with anti-HA antibody
(Sigma-Aldrich, St. Louis, MO USA), with empty vector serving as a negative
control. Stable clones of HA-PP2Acα and EV were grown in RPMI 1640
supplemented with 10% FBS and 0.5mg/ml G418 in all further experiments.
Drug Treatment and Cell lysate preparation. Stably transfected ad-293
HA-PP2Ac and empty vector cells were treated with varying concentrations of
lenalidomide, pomalidomide, and thalidomide dissolved in DMSO. Cells were
grown at 0.8x106/ml overnight in 35mm culture dishes before drug addition, or
equivalent volume of DMSO for 5’ at 37ºC before collection.
Cells were then washed with 1x TBS on ice and lysed in 150μl lysis buffer
composed of 10mM Tris (pH 8), 50mM NaCl, 5mM EDTA, 1% Nonidet P-40, 1
μg/μl protease inhibitors leupeptin, aprotinin, and antipain, 1mM sodium
orthovanadate, 5mM NaF, and 1mM DTT for 30’ at 4ºC. Cellular extracts used in
phosphatase activity assay was prepared using the lysis buffer adjusted to pH
7.0, omitting ser/thr phosphatase inhibitor NaF (171). Protein concentration was
measured using Bradford reagent (Bio-Rad) and standardized with BSA. Cellular
lysates for Western Blot were stored at -80ºC, while lysates for phosphatase
assay were used immediately.
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Phosphatase activity assay. Enzymatic activity of PP2Acα was
determined following immunoprecipitation using a malachite green phosphatase
assay (Ser/Thr Phosphatase Assay Kit 1; Upstate) and methods adapted from
Katsiari et al. (171) as follows. 250ug whole cellular protein was incubated with
anti-HA sepharose beads (Sigma-Aldrich) to pull down HA-PP2Acα, or a
negative control mouse IgG antibody and Protein A/G agarose beads (Santa
Cruz Biotechnology), at 4ºC rocking for 2 hours. Beads were then washed 3
times in 700µl TBS, and one time in 500µl Ser/Thr Assay Buffer before finally
dissolved in 40ul Ser/Thr Assay Buffer. Samples were then incubated with
500µM of PP2Acα phosphor-peptide substrate (amino acid sequence: K-R-pT-IR-R) for 10 minutes at 30ºC constantly shaking. Supernatants (25µl) were then
added to a 96-well plate in triplicate and 100µl malachite green added to
measure free-phosphate in solution. Color was allowed to develop for 15 minutes
before read at 650nm on spectrophotometer. Phosphate concentrations
determined using the equation from a standard curve.
After incubation with p-peptide, beads were then re-suspended in lysis
buffer, boiled, and immunoprecipitated protein ran on an SDS-page gel (10%) to
ensure equal pull-down of PP2Ac amongst samples.
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T-cell isolation and stimulation. Peripheral blood from buffy coats of
healthy donors was obtained from the Southwest Florida Blood Services, St.
Petersburg, FL for purification of primary T-cells. T-cells were isolated using
RosetteSep® Human CD3+ T-cell Enrichment Cocktail (StemCell Technologies,
Vancouver, BC Canada) according to the manufacturer’s protocol. Primary Tcells, or Jurkat T-cell leukemia cell line, were treated with 10µM Len or DMSO
(vehicle control) for 1 day prior to stimulation. T-cells were then counted and
coated with anti-CD3 antibody (5µg/ml) (BD Biosciences, San Jose, CA USA) on
ice for 1 hour (10x106/sample group) before being washed and coated with antimouse Fc antibody (5.0µg/ml) (Thermo Scientific, Rockford, IL USA) on ice for 30
minutes. Cells were again washed and the TCR cross-linked through incubation
at 37oC for 15 minutes before lysis in PP2A lysis buffer described above.
Subsequent phosphatase assay and western blotting were performed as
previously described.
Virtual Modeling. Virtual chemical modeling of the three different IMiDs
(thalidomide, lenalidomide, and pomalidomide) and a known positive control,
fostriecin, was performed utilizing the PP2A crystal structure PDB 3K7V (2Å
resolution). Prior to simulations and analysis, PDB 3K7V was prepared using the
Schrödinger application Protein Prep (Schrödinger, L.L.C. Cambridge, MA USA)
to remove waters, correct histidine orientations and hydrogen bonds, and provide
“soft” energy minimization to relax protein structure. Protein structure was then
analyzed via the SiteMap application (Schrödinger, L.L.C. Cambridge, MA USA)
to identify potential binding sites, serving as a predictor to determine if the known
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binding site for small molecules could be located, which found the catalytic
pocket used for docking purposes.
The four compounds, lenalidomide, pomalidomide, thalidomide, and
fostriecin were prepared for docking using the LigPrep application (Schrödinger,
L.L.C. Cambridge, MA USA), creating a 3-dimensional geometry for the
structures and providing for alternative tautomers and ionization states (between
pH 5.0 and 9.0), alternative ring conformations, and diastereomers. Application
GLIDE (Schrödinger, L.L.C. Cambridge, MA USA) was used to estimate the free
energy of binding for fostriecin, thalidomide, lenalidomide and pomalidomide to
the PP2Acα heterodimer. Fostriecin is a known PP2Acα inhibitor (367) and was
used as a positive control in this experiment.
Site-directed mutagenesis. Site-directed mutagenesis of the HA-PP2Ac
plasmid performed using the QuikChange Site-Directed mutagenesis kit from
Agilent Technologies (Santa Clara, CA USA) per the manufacturer’s instructions.
Briefly, the pcDNA3 plasmid containing the HA-PP2Ac wild-type gene was
denatured and primers containing the codon for the desired mutation for PP2Ac
was annealed. Using PfuTurbo DNA polymerase, the mutagenic primers were
incorporated into the plasmid, resulting in nicked circular strands. The circular
dsDNA including the new mutation was then transformed into competent cells,
colonies were selected, grown up, and isolated using plasmid mini-prep kit
(Invitrogen, Carlsbad, CA USA). Plasmids were sequenced by the Moffitt Cancer
Center Molecular Biology core facility to ensure expression of the mutation. The
mutated plasmid DNA was then transfected into ad293 cells and stable clones
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were isolated as previously described. Successful plasmid expression in the
clones was measured through HA-tag expression via western blot. Evaluation of
mutated PP2Ac functional activity was performed using phosphatase activity
assays as previously described. Primers for generating the various PP2Ac
mutants

were:

W200F:

forward:

GAGGGTCCAATGTGTGACTTGCTGTTCTCAGATCCAGATG-3’,
CATCTG

5’reverse:

GATCTGAGAACAGCAAGTCACACATTGGACCCTC-3’;

5’-

R214A:

forward: 5’-GTGGTTGG GGTATATCTCCTGCAGGAGCTGGTTAC-3’, reverse:
3’-GTAACCAGCTCCTGCAGGAGA TATACCCCAACCAC-3’; H191G: forward:
5’-GCCTACAAGAAGTTCC CGGTGAGGGTCCAATGTGTG-3’
CACACATTGGACCCTCACCGGGAACTT CTTGTAGGC-3’
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reverse: 5’-

CHAPTER 5
Discussion
Therapeutic implications of thalidomide and the IMiDs have progressed
significantly since the thalidomide tragedy of the 1960s. From use as a sedative,
to

anti-angiogenic

and

anti-cancer

properties,

to

immune

modulating

mechanisms, there is great potential for lenalidomide and pomalidomide to be
used in a variety of diseases and malignancies. The use of lenalidomide in
del(5q) MDS revolutionized treatment of the disease and gave patients with few
options other than repeated transfusions and a bone marrow transplantation a
chance at long-term survival. Unlike most therapeutics that are designed to target
a particular pathway or molecule, approval of lenalidomide was accepted based
upon patient outcome without a complete understanding of the mechanism of
action. Once clinical usage of the IMiDs became more widespread, research into
the direct mode of action of the drugs in MDS and other malignancies escalated,
and is still a topic of intense investigation today.
Lenalidomide is a small molecule therapeutic with a multitude of actions in
several different diseases and cell types, contributing to the complexity and
difficulty in determining the exact molecular target. Lenalidomide is able to induce
apoptosis in MM and MDS dysplastic clones, as well as improve hematopoiesis
through preventing apoptosis within erythroid blasts. Lenalidomide and the IMiDs
also have strong immunomodulating capacity, where they can increase the
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proliferation, activation, and cytokine production in T-cells and proliferation and
ADCC in NK-cells. It is important for us to understand how lenalidomide has such
powerful immune-harnessing potential, as knowledge of therapeutic mechanisms
for immunomodulation could be used to create even better drugs with less side
effects or threat of teratogenicity to offspring. This information would also be
useful in determining whether lenalidomide would be a powerful immunotherapy
adjuvant in different tumor settings/combination therapies.
For these reasons, we set out to determine how lenalidomide functions in
augmenting T-cell proliferation and function in normal T-cells, and if improved
immune function in patients with MDS due to lenalidomide contributes to their
hematologic response. We were first able to discover that T-cells from MDS
patients are inherently hypo-responsive to stimulation, and that lenalidomide can
reverse this defect. Len can augment the Th-1 cytokine producing and
proliferation capacity both in vitro and in vivo in MDS patient T-cells. We also
discovered that an increase in immune activity through cytokine production,
proliferation, and naïve T-cell production actually correlated with hematologic
response in non-del(5q) patients (Chapter 2). These results are extremely
important in recognizing the importance of an active and responding immune
system in helping to eradicate the myeloid clone in MDS. This also raises the
question of predictability of whether or not non-del(5q) patients will respond to
lenalidomide therapy, as only 25% of them actually do? Ebert et al. described an
erythroid gene signature that could help predict whether or not non-del(5q)
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patients would respond to lenalidomide therapy, although the signature involves
a costly microarray only presently utilized by their institution (238).
We then determined that the phenotype of the T-cell compartment in MDS
patients prior to treatment with lenalidomide could potentially predict whether or
not patients would respond to the drug. We found that patients who had high
levels of Terminal Effector Memory T-cells, which are inherently CD28null, were
erythroid non-responders after lenalidomide treatment. We examined this further
and determined that not only the percentage of TTEM cells could potentially
predict non-responsiveness, but also an overall decrease in CD28+ cells in the Tcell compartment, whether CD8+ or CD4+ (Chapter 3). A group in Australia has
recently measured CD28 expression on MDS patient samples treated with
lenalidomide at their institution, and we are currently collaborating to validate this
predictive model. If true, testing for CD28 expression by flow cytometry in the
peripheral blood of MDS patients prior to any therapy may help determine
whether or not non-del(5q) patients should receive lenalidomide therapy, as they
are less likely to respond to the drug the higher their CD28-%.
These results are not only important for influencing therapeutic decisions,
but they point directly to a mode of action of lenalidomide in T-cells. Since
aberrant

accumulation

of

hypo-responsive

CD28-

T-cells

may

predict

lenalidomide responsiveness, one can hypothesize that CD28 is important for
lenalidomide mechanism of action in T-cells. Lenalidomide is known to possess
the ability to induce proliferation of T-cells in the absence of co-stimulation or
external ligation of the CD28 receptor, alluding to the importance of CD28 in
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lenalidomide mechanism of action. We have shown that although lenalidomide
can induce proliferation and function of T-cells in the absence of external
receptor ligation, the presence of the CD28 receptor with its internal ITAM motifs
is essential for lenalidomide action. Lack of the CD28 receptor, either in naturally
occurring CD28- T-cells, or through in vitro shRNA knockdown, renders
lenalidomide incapable of inducing a proliferative or cytokine response. It is
therefore likely that receptor expression is necessary to act as a scaffold for
CD28 downstream signaling molecules that lead to increased IL-2 expression
and proliferation. Increased pCREB binding to the CD28-Response Element on
the IL-2 promoter further supports this hypothesis (Chapter 3).
Although we have discovered that CD28 expression is necessary for len
action, and that len likely acts through inhibition of a negative regulatory signal,
the direct molecular target remains elusive. There are several potential
molecules that could be targeted by lenalidomide, including phosphatases and
E3-ubiquitin ligases. Thalidomide was shown to target the E3 ubiquitin ligase
Cereblon in chicken and zebrafish embryos to cause teratogenesis (248).
Although this group was able to prove direct binding of thalidomide to cereblon,
therefore blocking the ability of the CRBN-Cul4-DDB1 E3-ligase complex to
function, it is unclear whether this occurs in T-cells as well. Cereblon was first
discovered in the brain to be involved in memory and learning, and there is
actually no known function in T-cells. Interestingly, Lopez-Girona et al. have
determined that CRBN expression in T-cells is essential for lenalidomide-induced
IL-2 and TNF-α production (257). Preliminary results, however, from T-cells
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isolated from cereblon knockout mice show an increase in IL-2 production in the
presence of anti-CD3 stimulation, indicating that cereblon may play a role in
negative regulation of IL-2 production (data not shown). Germline deletion of
cereblon in mice has no detrimental effect on limb generation, lymphocyte
populations, or overall T-cell phenotype/function. Therefore, it is unclear what
role cereblon plays in T-cell function or what particular targets in the T-cell
signaling pathway cereblon could bind to, and are topics of further investigation
in our lab.
Another E3 ubiquitin ligase that plays a major role in T-cell anergy
induction and preventing non-specific T-cell activation through ubiquitination of
downstream CD28 targets is cbl-b. Although direct inhibition of cbl-b by
lenalidomide was not identified (data not shown), T-cells isolated from cbl-b
knockout mice are hyper-responsive to anti-CD3 stimulation through their ability
to proliferate/function without anti-CD28 ligation (155, 156). The IL-2 production
from these mouse T-cells stimulated with anti-CD3 antibody alone is nearly
identical to cells treated with lenalidomide in the presence of anti-CD3
stimulation, indicating a potential link. Since there is solid evidence lenalidomide
inhibits multiple E3 ubiquitin ligases (cereblon and MDM2) in a variety of cell
types (multiple myeloma cells, erythroid cells, etc), other potential E3 ligases as
targets are completely plausible.
Another known target of lenalidomide in apoptotic induction within the
del(5q) myeloid clone is protein phosphatase 2A. Since PP2A is involved in a
variety of cellular processes with varying roles, we have demonstrated that
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lenalidomide not only inhibits PP2A activity within MDS to prohibit cell cycle
progression, but in primary T-cells as well. PP2A is another negative regulator of
CD28 signaling and over-expression has been implicated in the reduction of IL-2
secreting capacity in T-cells from SLE patients (170, 171). PP2A can directly bind
to and de-phosphorylate the CD28 receptor, and inhibition through lenalidomide
increases ITAM phosphorylation and prolongs downstream signaling. These data
suggest multiple protein targets for lenalidomide not only in various cell types, but
within T-cells as well, likely to share a negative regulatory role within the CD28
pathway.
Taken together, the data presented in this dissertation have several
implications within cancer immunotherapy and MDS. Lenalidomide is likely to be
a potent immunotherapy adjuvant, through its ability to augment T-cell
proliferation and function in the absence of co-stimulatory signals that are often
down-regulated on solid and liquid tumors. Lenalidomide has already been
investigated and is used in several clinical trials in combination with cellular
vaccines, but theoretically could also be used in combination with antibody
therapies such as ipilimumab and anti-PD1 therapy that target the co-inhibitory
pathway. Prevention of co-inhibitory signals while simultaneously activating costimulation

could

counteract

problems

of

T-cell

tolerance

and

non-

responsiveness in cancer, and result in a robust antigen-specific cytotoxic T-cell
response, while providing additional help through NK-cell mediated ADCC and
killing.
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Importantly, CD28 expression on primary T-cells from cancer patients
could be used to identify those patients that would actually respond to the
immunomodulating therapy. As described previously, CD28 expression is lost on
CD8+ cytotoxic T-cells through the aging process. The greatest risk factor for
cancer is age, and since the median age of onset of MDS is 76 and most cancers
arise in the elderly, measuring the expression of CD28 inherent on the T-cell
population would be advantageous to predict responses to lenalidomide therapy.
Through our experiments we have determined the likely pathway for
lenalidomide’s mechanism of action, and a potential target that could be utilized
by even other therapies to garner increases in T-cell function.
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